<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>ADVATE, INN-octocog alfa</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-align:center;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	text-align:center;
	line-height:120%;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	layout-grid-mode:line;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
span.MsoFootnoteReference
	{vertical-align:super;}
span.MsoPageNumber
	{font-family:"Arial",sans-serif;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0in;
	text-align:center;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:gray;
	font-weight:bold;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:6.0pt;
	margin-right:-1.4pt;
	margin-bottom:0in;
	margin-left:-1.85pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.a
	{mso-style-name:"\0022";}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	margin-top:1.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	text-align:center;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.NormalCSA, li.NormalCSA, div.NormalCSA
	{mso-style-name:"Normal CSA";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	font-family:"Tahoma",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";}
p.Body, li.Body, div.Body
	{mso-style-name:Body;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.5pt;
	margin-left:0in;
	text-align:justify;
	line-height:110%;
	font-size:10.5pt;
	font-family:"Arial",sans-serif;}
p.Revisie, li.Revisie, div.Revisie
	{mso-style-name:Revisie;
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Bibliografie, li.Bibliografie, div.Bibliografie
	{mso-style-name:Bibliografie;
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-weight:bold;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-weight:bold;
	font-style:italic;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	color:gray;
	font-weight:bold;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	color:gray;
	font-weight:bold;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
p.Duidelijkcitaat, li.Duidelijkcitaat, div.Duidelijkcitaat
	{mso-style-name:"Duidelijk citaat";
	mso-style-link:"Duidelijk citaat Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.DuidelijkcitaatChar
	{mso-style-name:"Duidelijk citaat Char";
	mso-style-link:"Duidelijk citaat";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.Lijstalinea, li.Lijstalinea, div.Lijstalinea
	{mso-style-name:Lijstalinea;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
p.Geenafstand, li.Geenafstand, div.Geenafstand
	{mso-style-name:"Geen afstand";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
p.Citaat, li.Citaat, div.Citaat
	{mso-style-name:Citaat;
	mso-style-link:"Citaat Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
span.CitaatChar
	{mso-style-name:"Citaat Char";
	mso-style-link:Citaat;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
p.Kopvaninhoudsopgave, li.Kopvaninhoudsopgave, div.Kopvaninhoudsopgave
	{mso-style-name:"Kop van inhoudsopgave";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:center;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BookmarkB, li.BookmarkB, div.BookmarkB
	{mso-style-name:"Bookmark B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
p.DocText, li.DocText, div.DocText
	{mso-style-name:"Doc Text";
	mso-style-link:"Doc Text Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FooterAgency, li.FooterAgency, div.FooterAgency
	{mso-style-name:"Footer \(Agency\)";
	mso-style-link:"Footer \(Agency\) Char Char";
	margin:0in;
	line-height:normal;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.FooterAgencyCharChar
	{mso-style-name:"Footer \(Agency\) Char Char";
	mso-style-link:"Footer \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.ColorfulShading-Accent11, li.ColorfulShading-Accent11, div.ColorfulShading-Accent11
	{mso-style-name:"Colorful Shading - Accent 11";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.DocTextChar1
	{mso-style-name:"Doc Text Char1";
	mso-style-link:"Doc Text";
	font-family:"Arial Unicode MS",serif;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.Heading1Agency, li.Heading1Agency, div.Heading1Agency
	{mso-style-name:"Heading 1 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:13.5pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading2Agency, li.Heading2Agency, div.Heading2Agency
	{mso-style-name:"Heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading3Agency, li.Heading3Agency, div.Heading3Agency
	{mso-style-name:"Heading 3 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading4Agency, li.Heading4Agency, div.Heading4Agency
	{mso-style-name:"Heading 4 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.Heading5Agency, li.Heading5Agency, div.Heading5Agency
	{mso-style-name:"Heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading6Agency, li.Heading6Agency, div.Heading6Agency
	{mso-style-name:"Heading 6 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading7Agency, li.Heading7Agency, div.Heading7Agency
	{mso-style-name:"Heading 7 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading8Agency, li.Heading8Agency, div.Heading8Agency
	{mso-style-name:"Heading 8 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.Heading9Agency, li.Heading9Agency, div.Heading9Agency
	{mso-style-name:"Heading 9 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	text-indent:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.No-numheading2Agency, li.No-numheading2Agency, div.No-numheading2Agency
	{mso-style-name:"No-num heading 2 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;
	font-style:italic;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<h1>SUMMARY OF PRODUCT CHARACTERISTICS</h1>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU powder
and solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains nominally&nbsp;250&nbsp;IU human coagulation factor VIII (rDNA),
octocog alfa. ADVATE contains approximately&nbsp;50&nbsp;IU per ml of human
coagulation factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is
approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB style='text-transform:uppercase'>4.</span><span lang=EN-GB> <span
style='text-transform:uppercase'>Clinical particulars</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of
units of factor VIII is expressed in International Units (IU), which are
related to the WHO standard for factor VIII products. Factor VIII activity in
plasma is expressed either as a percentage (relative to normal human plasma) or
in IUs (relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII
activity is equivalent to that quantity of factor VIII in one ml of normal human
plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding that&nbsp;1&nbsp;IU
factor VIII per kg body weight raises the plasma factor VIII activity by&nbsp;2&nbsp;IU/dl.
The required dose is determined using the following formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Required units
(IU)&nbsp;=&nbsp;body weight (kg) x desired factor VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.04%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life threatening
  haemorrhages.</span></p>
  </td>
  <td width="26%" valign=top style='width:26.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.04%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or
  more until pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours
  for patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209; and
  postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.04%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) until adequate wound healing, then
  continue therapy for at least another&nbsp;7&nbsp;days to maintain a factor
  VIII activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is
advised to guide the dose to be administered and the frequency of repeated
injections. In the case of major surgical interventions in particular, precise
monitoring of the substitution therapy by means of plasma factor VIII activity
assay is indispensable. Individual patients may vary in their response to
factor VIII, achieving different levels of <i>in vivo</i> recovery and
demonstrating different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult&nbsp;patients. In patients under the age of 6, doses of 20 to
50&nbsp;IU of factor VIII per kg body weight 3&nbsp;to 4 times weekly are
recommended for prophylactic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the
medicinal product before </span><span lang=EN-GB>administration, see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients </span><span lang=EN-GB>listed
in section 6.1 </span><span lang=EN-GB>or to mouse or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms of
hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised
urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of
shock, standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more than&nbsp;100&nbsp;exposure
days who have a previous history of inhibitor development. Therefore, it is
recommended to monitor all patients carefully for inhibitor occurrence
following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical
observations and laboratory tests. If the expected factor VIII activity plasma
levels are not attained, or if bleeding is not controlled with an appropriate
dose, testing for factor VIII inhibitor presence should be performed. In
patients with high levels of inhibitor, factor VIII therapy may not be
effective and other therapeutic options should be considered. Management of
such patients should be directed by physicians with experience in the care of
haemophilia and factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central
venous access device (CVAD) is required, risk of CVAD&#8209;related
complications including local infections, bacteremia and catheter site
thrombosis should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal><a name="_Hlk63260851"><u><span lang=EN-GB>Sodium</span></u></a></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and
batch number of the product are recorded </span><span lang=EN-GB>in order to
maintain a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 </span></b><b><span
lang=EN-GB>Fertility, </span></b><b><span lang=EN-GB>pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Animal reproduction studies have not been conducted with factor
VIII. Based on the rare</span><span class=MsoCommentReference><span lang=EN-GB
style='font-size:8.0pt'> </span></span><span lang=EN-GB>occurrence of
haemophilia A in women, experience regarding the use of factor VIII during
pregnancy and breast&#8209;feeding is not available. Therefore, factor VIII
should be used during pregnancy and breast-feeding only if clearly indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE</span><span lang=EN-GB> has no influence on the ability to
drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Summary of the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE
reporting in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The
ADRs that occurred in the highest frequency were development of neutralising antibodies
to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills,
flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea,
restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster
protein with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A
treated with factor VIII, including with ADVATE. If such inhibitors occur, the
condition will manifest itself as an insufficient clinical response. In such
cases, it is recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical
trials and from spontaneous reporting. The table is according to the MedDRA
system organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following
convention: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to
&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000),
not known (cannot be estimated from the available data). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 4.0pt 0in 4.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.36%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 4.0pt 0in 4.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 4.0pt 0in 4.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 4.0pt 0in 4.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.15in'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:.15in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:.15in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="44%" rowspan=2 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.5pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.5pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.36%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injury, poisoning and procedural complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>a) Calculated based on total number of patients who
received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)<b> </b>The unexpected
decrease in coagulation factor VIII levels occurred in one patient during
continuous infusion of ADVATE following surgery (postoperative days&nbsp;10&#8209;14).
Haemostasis was maintained at all times during this period and both plasma
factor VIII levels and clearance rates returned to appropriate levels by postoperative
day&nbsp;15. Factor VIII inhibitor assays performed after completion of
continuous infusion and at study termination were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>c) ADR explained in the
section below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs =
previously-treated patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the&nbsp;229&nbsp;treated
patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell
protein,&nbsp;3&nbsp;showed a statistically significant upward trend in titres,&nbsp;4&nbsp;displayed
sustained peaks or transient spikes and one patient had both but no clinical
symptoms. Of the&nbsp;229&nbsp;treated patients who were assessed for
antibodies to murine IgG,&nbsp;10&nbsp;showed a statistically significant
upward trend,&nbsp;2&nbsp;displayed a sustained peak or transient spike and one
patient had both. Four of these patients reported isolated events of urticaria,
pruritus, rash, and slightly elevated eosinophil counts amongst repeated
exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
reactions include anaphylaxis and have been manifested by dizziness, paresthesias,
rash, flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs), and
catheter&#8209;related complications, no age&#8209;specific differences in ADRs
were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No symptoms of
overdose with recombinant coagulation factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic group:
antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The factor
VIII/von Willebrand Factor complex consists of two molecules (factor VIII and
von Willebrand Factor) with different physiological functions. ADVATE contains
recombinant coagulation factor VIII (octocog alfa), a glycoprotein that is biologically
equivalent to the factor VIII glycoprotein found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient,
octocog alfa binds to endogenous von Willebrand Factor in the patients
circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,
accelerating the conversion of Factor X to activated Factor X. Activated Factor
X converts prothrombin to thrombin. Thrombin then converts fibrinogen into
fibrin and a clot can be formed. Haemophilia A is a sex&#8209;linked hereditary
disorder of blood coagulation due to decreased levels of factor VIII activity
and results in profuse bleeding into joints, muscles or internal organs, either
spontaneously or as a result of accidental or surgical trauma. The plasma
levels of factor VIII are increased by replacement therapy, thereby enabling a
temporary correction of the factor VIII deficiency and correction of the
bleeding tendency.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done for&nbsp;30&nbsp;<span
style='letter-spacing:-.15pt'>paediatric</span> subjects on ITI (in study&nbsp;060703).
A non-interventional prospective registry (PASS-INT-004) documented ITI in 44
paediatric and adult subjects of whom 36 completed ITI therapy. Data show that
immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23)
with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a&nbsp;specific
formula) was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated
patients with severe to moderately severe haemophilia A (baseline factor VIII &#8804;&nbsp;2%).
The analysis of plasma samples was conducted in a central laboratory using a
one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>Parameter (mean  standard deviation)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.02%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.72%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
   layout-grid-mode:line'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.62%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>Older Children</span></p>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.02%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="19%" valign=top style='width:19.62%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left;page-break-after:
  avoid'><span lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="13%" valign=top style='width:13.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="15%" valign=top style='width:15.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>Adjusted
  Incremental Recovery at Cmax (IU/dL per IU/kg)a</span></p>
  </td>
  <td width="13%" valign=top style='width:13.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="13%" valign=top style='width:13.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="13%" valign=top style='width:13.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR style='font-size:10.0pt'>Maximum Plasma Concentration Post Infusion
  (IU/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="13%" valign=top style='width:13.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="13%" valign=top style='width:13.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="13%" valign=top style='width:13.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="13%" valign=top style='width:13.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety and haemostatic efficacy of ADVATE in the paediatric
population are similar to that of adult patients. Adjusted recovery and
terminal half&#8209;life (t<sub></sub>) was approximately&nbsp;20% lower in
young children (less than&nbsp;6&nbsp;years of age) than in adults, which may
be due in part to the known higher plasma volume per kilogram body weight in
younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacokinetic data with ADVATE on previously untreated patients
are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After reconstitution,
from a microbiological point of view, the product should be used immediately. However,
chemical and physical in&#8209;use stability has been demonstrated for&nbsp;3&nbsp;hours
at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months storage
at room temperature should be recorded on the product carton. The product may
not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator
(2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with BAXJECT
II device: Keep the product vial in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in BAXJECT
III system: Keep the sealed blister in the outer carton in order to protect
from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Both the powder vial and the
vial containing 5&nbsp;ml solvent are of type I glass closed with chlorobutyl
rubber stoppers. The product is provided in one of the following
configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;5&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 5 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be
administered intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use solutions
that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Reconstitution
with the BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take both the ADVATE powder and solvent vials from the
refrigerator and let them reach room temperature (between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder stopper.
The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="_Hlk22564792"><span lang=EN-GB><img
border=0 width=630 height=183 id="Picture 1"
src="Advate-h-520-e_files/image001.jpg"></span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the </span><span
lang=EN-GB>BAXJECT&nbsp;III system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for
reconstitution) from the refrigerator and let it reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open<a name="_Hlk374420263"> the ADVATE package
by peeling away the lid. <span style='color:black'>Remove </span>the
BAXJECT&nbsp;III system <span style='color:black'>from the blister</span>.</a></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="_Hlk374420333"><span lang=EN-GB>4. Place the ADVATE on a
flat surface with the solvent vial on top (Fig. 1). The solvent vial has a blue
stripe. Do not remove the blue cap until instructed in a later step.</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="_Hlk374420401"><span lang=EN-GB>5. With one hand holding
the ADVATE in the BAXJECT&nbsp;III system, press down firmly on the solvent
vial with the other hand until the system is fully collapsed and the solvent
flows down into the ADVATE vial (Fig. 2). Do not tilt the system until the
transfer is complete.</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="_Hlk374420441"><span lang=EN-GB>6. Verify that the solvent
transfer is complete.</span></a><span lang=EN-GB> Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image003.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image004.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral
medicinal products should be inspected for particulate matter prior to administration,
whenever solution and container permit. Only a clear and colourless solution
should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>3. Disconnect the
syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4. Attach a butterfly
needle to the syringe. Inject intravenously. The solution should be
administered slowly, at a rate as determined by the patients comfort level,
not to exceed&nbsp;10&nbsp;ml per minute. The pulse rate should be determined
before and during administration of ADVATE. Should a significant increase
occur, reducing the rate of administration or temporarily interrupting the
injection usually allows the symptoms to disappear promptly (see sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="_Hlk27641873"><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/03/271/001</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/03/271/011</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE&nbsp;500&nbsp;IU powder and solvent for solution for
injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial contains
nominally&nbsp;500&nbsp;IU human coagulation factor VIII (rDNA), octocog alfa. ADVATE
contains approximately&nbsp;100&nbsp;IU per ml of human coagulation factor VIII
(rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is
approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of
units of factor VIII is expressed in International Units (IU), which are
related to the WHO standard for factor VIII products. Factor VIII activity in
plasma is expressed either as a percentage (relative to normal human plasma) or
in IUs (relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII
activity is equivalent to that quantity of factor VIII in one ml of normal human
plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the
following formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Required units (IU)&nbsp;=&nbsp;body
weight (kg) x desired factor VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life
  threatening haemorrhages.</span></p>
  </td>
  <td width="26%" valign=top style='width:26.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more
  until pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours
  for patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.98%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209; and
  postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) until adequate wound healing, then
  continue therapy for at least another&nbsp;7&nbsp;days to maintain a factor
  VIII activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is
advised to guide the dose to be administered and the frequency of repeated
injections. In the case of major surgical interventions in particular, precise
monitoring of the substitution therapy by means of plasma factor VIII activity
assay is indispensable. Individual patients may vary in their response to
factor VIII, achieving different levels of <i>in vivo</i> recovery and
demonstrating different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU of
factor VIII per kg body weight 3 to 4 times weekly are recommended for
prophylactic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution of the medicinal product before administration,
see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
</span><span lang=EN-GB>listed in section 6.1 </span><span lang=EN-GB>or to
mouse or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms of
hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised
urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of shock,
standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of recurrent
inhibitor (low titre) have been observed after switching from one factor VIII
product to another in previously treated patients with more
than&nbsp;100&nbsp;exposure days who have a previous history of inhibitor
development. Therefore, it is recommended to monitor all patients carefully for
inhibitor occurrence following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical observations
and laboratory tests. If the expected factor VIII activity plasma levels are
not attained, or if bleeding is not controlled with an appropriate dose,
testing for factor VIII inhibitor presence should be performed. In patients
with high levels of inhibitor, factor VIII therapy may not be effective and
other therapeutic options should be considered. Management of such patients
should be directed by physicians with experience in the care of haemophilia and
factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central
venous access device (CVAD) is required, risk of CVAD&#8209;related
complications including local infections, bacteremia and catheter site
thrombosis should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 10 mg sodium per vial, equivalent to 0.5 % of the WHO
recommended maximum daily intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><s>This medicinal product contains
less than 1 mmol sodium (23 mg) per vial, that is to say essentially
sodium-free.</s></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and batch
number of the product are recorded </span><span lang=EN-GB>in order to maintain
a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal
reproduction studies have not been conducted with factor VIII. Based on the
rare occurrence of haemophilia A in women, experience regarding the use of
factor VIII during pregnancy and breast&#8209;feeding is not available. Therefore,
factor VIII should be used during pregnancy and breast-feeding only if clearly
indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>ADVATE has no influence on the
ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Summary of the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE
reporting in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The
ADRs that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills, flushing,
generalised urticaria, headache, hives, hypotension, lethargy, nausea,
restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster
protein with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated
with factor VIII, including with ADVATE. If such inhibitors occur, the condition
will manifest itself as an insufficient clinical response. In such cases, it is
recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following table&nbsp;2&nbsp;provides
the frequency of adverse drug reactions in clinical trials and from spontaneous
reporting. The table is according to the MedDRA system organ classification
(SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following convention:
very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to &lt;&nbsp;1/10),
uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000&nbsp;to
&lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), not known (cannot be
estimated from the available data). Within each frequency grouping, undesirable
effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injury, poisoning and procedural complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>a) Calculated based on total number of patients
who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred
in one patient during continuous infusion of ADVATE following surgery
(postoperative days&nbsp;10&#8209;14). Haemostasis was maintained at all times
during this period and both plasma factor VIII levels and clearance rates
returned to appropriate levels by postoperative day&nbsp;15. Factor VIII
inhibitor assays performed after completion of continuous infusion and at study
termination were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>c) ADR explained in the section
below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs =
previously-treated patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically
significant upward trend in titres,&nbsp;4&nbsp;displayed sustained peaks or
transient spikes and one patient had both but no clinical symptoms. Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to murine
IgG,&nbsp;10&nbsp;showed a statistically significant upward trend,&nbsp;2&nbsp;displayed
a sustained peak or transient spike and one patient had both. Four of these
patients reported isolated events of urticaria, pruritus, rash, and slightly
elevated eosinophil counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
reactions include anaphylaxis and have been manifested by dizziness, paresthesias,
rash, flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
ADRs were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No symptoms of
overdose with recombinant coagulation factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The factor VIII/von
Willebrand Factor complex consists of two molecules (factor VIII and von Willebrand
Factor) with different physiological functions. ADVATE contains recombinant
coagulation factor VIII (octocog alfa), a glycoprotein that is biologically
equivalent to the factor VIII glycoprotein found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient,
octocog alfa binds to endogenous von Willebrand Factor in the patients
circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,
accelerating the conversion of Factor X to activated Factor X. Activated Factor
X converts prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin
and a clot can be formed. Haemophilia A is a sex&#8209;linked hereditary
disorder of blood coagulation due to decreased levels of factor VIII activity
and results in profuse bleeding into joints, muscles or internal organs, either
spontaneously or as a result of accidental or surgical trauma. The plasma
levels of factor VIII are increased by replacement therapy, thereby enabling a
temporary correction of the factor VIII deficiency and correction of the
bleeding tendency.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a&nbsp;sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done for&nbsp;30&nbsp;paediatric
subjects on ITI (in study&nbsp;060703). A non-interventional prospective
registry (PASS-INT-004) documented ITI in 44 paediatric and adult subjects of
whom 36 completed ITI therapy. Data show that immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an individualized
pharmacokinetic guided dosing regimen (within a range of 20 to 80 IU of factor
VIII per kg body weight at intervals of 72  6 hours, n=23) with a standard
prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours, n=30). The
pharmacokinetic guided dosing regimen (according to a&nbsp;specific formula)
was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated
patients with severe to moderately severe haemophilia A (baseline factor VIII &#8804;&nbsp;2%).
The analysis of plasma samples was conducted in a central laboratory using a
one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="25%" valign=top style='width:25.8%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="11%" valign=top style='width:11.96%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.52%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="17%" valign=top style='width:17.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="25%" valign=top style='width:25.8%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="14%" valign=top style='width:14.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="17%" valign=top style='width:17.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.8%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>Adjusted
  Incremental Recovery at Cmax (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="11%" valign=top style='width:11.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="17%" valign=top style='width:17.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.8%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="17%" valign=top style='width:17.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.8%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR style='font-size:10.0pt'>Maximum Plasma Concentration Post Infusion
  (IU/dl)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="17%" valign=top style='width:17.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.8%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="14%" valign=top style='width:14.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.8%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="17%" valign=top style='width:17.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="25%" valign=top style='width:25.8%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="12%" valign=top style='width:12.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
haemostatic efficacy of ADVATE in the paediatric population are similar to that
of adult patients. Adjusted recovery and terminal half&#8209;life (t<sub></sub>)
was approximately&nbsp;20% lower in young children (less than&nbsp;6&nbsp;years
of age) than in adults, which may be due in part to the known higher plasma
volume per kilogram body weight in younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetic
data with ADVATE on previously untreated patients are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Sterilised water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months
storage at room temperature should be recorded on the product carton. The
product may not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Both the powder vial and the vial containing 5&nbsp;ml solvent are
of type I glass closed with chlorobutyl rubber stoppers. The product is
provided in one of the following configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;5&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 5 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be administered
intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Reconstitution
with the BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take both the ADVATE powder and solvent vials from the
refrigerator and let them reach room temperature (between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder stopper.
The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8.<b> </b>Swirl gently
until all material is dissolved. Be sure that the ADVATE powder is completely
dissolved, otherwise not all reconstituted solution will pass through the
device filter. The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute).
After reconstitution the solution should be clear, colourless and free from
foreign particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image005.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the </span><span
lang=EN-GB>BAXJECT&nbsp;III system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for
reconstitution) from the refrigerator and let it reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass
through the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image006.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image007.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral medicinal
products should be inspected for particulate matter prior to administration,
whenever solution and container permit. Only a clear and colourless solution
should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4. Attach a butterfly
needle to the syringe. Inject intravenously. The solution should be
administered slowly, at a rate as determined by the patients comfort level,
not to exceed&nbsp;10&nbsp;ml per minute. The pulse rate should be determined
before and during administration of ADVATE. Should a significant increase
occur, reducing the rate of administration or temporarily interrupting the
injection usually allows the symptoms to disappear promptly (see
sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>EU/1/03/271/002</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>EU/1/03/271/012</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Date of first authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU powder
and solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial contains
nominally&nbsp;1000&nbsp;IU human coagulation factor VIII (rDNA), octocog alfa.
ADVATE contains approximately&nbsp;200&nbsp;IU per ml of human coagulation
factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is
approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>For the full list of
excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of
units of factor VIII is expressed in International Units (IU), which are
related to the WHO standard for factor VIII products. Factor VIII activity in
plasma is expressed either as a percentage (relative to normal human plasma) or
in IUs (relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII
activity is equivalent to that quantity of factor VIII in one ml of normal human
plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the following
formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Required units
(IU)&nbsp;=&nbsp;body weight (kg) x desired factor VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in bleeding
  episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life threatening
  haemorrhages.</span></p>
  </td>
  <td width="26%" valign=top style='width:26.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age&nbsp;of&nbsp;6) for at least&nbsp;1&nbsp;day,
  until the bleeding episode, as indicated by pain, is resolved or healing is
  achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more
  until pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours
  for patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) until adequate wound healing, then continue
  therapy for at least another&nbsp;7&nbsp;days to maintain a factor VIII
  activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is
advised to guide the dose to be administered and the frequency of repeated
injections. In the case of major surgical interventions in particular, precise
monitoring of the substitution therapy by means of plasma factor VIII activity assay
is indispensable. Individual patients may vary in their response to factor
VIII, achieving different levels of <i>in vivo</i> recovery and demonstrating
different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU
of factor VIII per kg body weight 3 to 4 times weekly are recommended for
prophylactic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the
medicinal product before </span><span lang=EN-GB>administration, see
section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
</span><span lang=EN-GB>listed in section 6.1 </span><span lang=EN-GB>or to mouse
or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms of
hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised urticaria,
tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of
shock, standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually IgG
</span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more
than&nbsp;100&nbsp;exposure days who have a previous history of inhibitor
development. Therefore, it is recommended to monitor all patients carefully for
inhibitor occurrence following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical
observations and laboratory tests. If the expected factor VIII activity plasma
levels are not attained, or if bleeding is not controlled with an appropriate
dose, testing for factor VIII inhibitor presence should be performed. In
patients with high levels of inhibitor, factor VIII therapy may not be
effective and other therapeutic options should be considered. Management of
such patients should be directed by physicians with experience in the care of
haemophilia and factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central venous
access device (CVAD) is required, risk of CVAD&#8209;related complications
including local infections, bacteremia and catheter site thrombosis should be
considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk63260190"><u><span
lang=EN-GB>Sodium</span></u></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><s>This medicinal product
contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially
sodium-free.</s></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and
batch number of the product are recorded </span><span lang=EN-GB>in order to
maintain a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal
reproduction studies have not been conducted with factor VIII. Based on the
rare occurrence of haemophilia A in women, experience regarding the use of
factor VIII during pregnancy and breast&#8209;feeding is not available. Therefore,
factor VIII should be used during pregnancy and breast-feeding only if clearly
indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE has no
influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Summary of
the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE reporting
in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The ADRs
that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills,
flushing, generalised urticaria, headache, hives, hypotension, lethargy,
nausea, restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster
protein with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A
treated with factor VIII, including with ADVATE. If such inhibitors occur, the
condition will manifest itself as an insufficient clinical response. In such
cases, it is recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical
trials and from spontaneous reporting. The table is according to the MedDRA
system organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following
convention: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to
&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000),
not known (cannot be estimated from the available data). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.4%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.4%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injury, poisoning and procedural complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>a) Calculated based on total number of patients
who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred
in one patient during continuous infusion of ADVATE following surgery (postoperative
days&nbsp;10&#8209;14). Haemostasis was maintained at all times during this period
and both plasma factor VIII levels and clearance rates returned to appropriate
levels by postoperative day&nbsp;15. Factor VIII inhibitor assays performed after
completion of continuous infusion and at study termination were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>c) ADR explained in the section below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs =
previously-treated patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically significant
upward trend in titres,&nbsp;4&nbsp;displayed sustained peaks or transient spikes
and one patient had both but no clinical symptoms. Of the&nbsp;229&nbsp;treated
patients who were assessed for antibodies to murine IgG,&nbsp;10&nbsp;showed a
statistically significant upward trend,&nbsp;2&nbsp;displayed a sustained peak
or transient spike and one patient had both. Four of these patients reported
isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil
counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type reactions
include anaphylaxis and have been manifested by dizziness, paresthesias, rash,
flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
ADRs were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No symptoms of
overdose with recombinant coagulation factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The factor
VIII/von Willebrand Factor complex consists of two molecules (factor VIII and
von Willebrand Factor) with different physiological functions. ADVATE contains
recombinant coagulation factor VIII (octocog alfa), a glycoprotein that is biologically
equivalent to the factor VIII glycoprotein found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient,
octocog alfa binds to endogenous von Willebrand Factor in the patients
circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,
accelerating the conversion of Factor X to activated Factor X. Activated Factor
X converts prothrombin to thrombin. Thrombin then converts fibrinogen into
fibrin and a clot can be formed. Haemophilia A is a sex&#8209;linked hereditary
disorder of blood coagulation due to decreased levels of factor VIII activity
and results in profuse bleeding into joints, muscles or internal organs, either
spontaneously or as a result of accidental or surgical trauma. The plasma
levels of factor VIII are increased by replacement therapy, thereby enabling a
temporary correction of the factor VIII deficiency and correction of the
bleeding tendency.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done for&nbsp;30&nbsp;<span
style='letter-spacing:-.15pt'>paediatric</span> subjects on ITI (in study&nbsp;060703).
A non-interventional prospective registry (PASS-INT-004) documented ITI in 44
paediatric and adult subjects of whom 36 completed ITI therapy. Data show that
immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23)
with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a&nbsp;specific
formula) was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated
patients with severe to moderately severe haemophilia A (baseline factor VIII &#8804;&nbsp;2%).
The analysis of plasma samples was conducted in a central laboratory using a
one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>Adjusted
  Incremental Recovery at Cmax (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR style='font-size:10.0pt'>Maximum Plasma Concentration Post Infusion
  (IU/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety and haemostatic efficacy of ADVATE in the paediatric
population are similar to that of adult patients. Adjusted recovery and
terminal half&#8209;life (t<sub></sub>) was approximately&nbsp;20% lower in
young children (less than&nbsp;6&nbsp;years of age) than in adults, which may
be due in part to the known higher plasma volume per kilogram body weight in
younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetic
data with ADVATE on previously untreated patients are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months
storage at room temperature should be recorded on the product carton. The
product may not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Both the powder vial and the vial containing 5&nbsp;ml solvent are
of type I glass closed with chlorobutyl rubber stoppers. The product is
provided in one of the following configurations:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;5&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 5 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be administered
intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Reconstitution with the BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take both the ADVATE powder and solvent vials from the
refrigerator and let them reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder
stopper. The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image005.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Reconstitution with the </span><span lang=EN-GB>BAXJECT&nbsp;III
system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for
reconstitution) from the refrigerator and let it reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass
through the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image008.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image006.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image007.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral medicinal
products should be inspected for particulate matter prior to administration,
whenever solution and container permit. Only a clear and colourless solution
should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4. Attach a butterfly
needle to the syringe. Inject intravenously. The solution should be
administered slowly, at a rate as determined by the patients comfort level,
not to exceed&nbsp;10&nbsp;ml per minute. The pulse rate should be determined
before and during administration of ADVATE. Should a significant increase
occur, reducing the rate of administration or temporarily interrupting the
injection usually allows the symptoms to disappear promptly (see
sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>EU/1/03/271/003</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>EU/1/03/271/013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Date of first authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU powder
and solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial contains
nominally&nbsp;1500&nbsp;IU human coagulation factor VIII (rDNA), octocog alfa.
ADVATE contains approximately&nbsp;300&nbsp;IU per ml of human coagulation
factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is
approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of
units of factor VIII is expressed in International Units (IU), which are
related to the WHO standard for factor VIII products. Factor VIII activity in
plasma is expressed either as a percentage (relative to normal human plasma) or
in IUs (relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII
activity is equivalent to that quantity of factor VIII in one ml of normal human
plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the
following formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Required units (IU)&nbsp;=&nbsp;body weight (kg) x desired factor
VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of haemorrhage/type
  of surgical procedure</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life threatening
  haemorrhages.</span></p>
  </td>
  <td width="26%" valign=top style='width:26.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more
  until pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours
  for patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) until adequate wound healing, then continue
  therapy for at least another&nbsp;7&nbsp;days to maintain a factor VIII
  activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is
advised to guide the dose to be administered and the frequency of repeated
injections. In the case of major surgical interventions in particular, precise
monitoring of the substitution therapy by means of plasma factor VIII activity assay
is indispensable. Individual patients may vary in their response to factor
VIII, achieving different levels of <i>in vivo</i> recovery and demonstrating
different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU
of factor VIII per kg body weight 3 to 4 times weekly are recommended for
prophylactic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the
medicinal product before </span><span lang=EN-GB>administration, see
section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
</span><span lang=EN-GB>listed in section 6.1 </span><span lang=EN-GB>or to mouse
or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms of
hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised urticaria,
tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of
shock, standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more
than&nbsp;100&nbsp;exposure days who have a previous history of inhibitor
development. Therefore, it is recommended to monitor all patients carefully for
inhibitor occurrence following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical
observations and laboratory tests. If the expected factor VIII activity plasma
levels are not attained, or if bleeding is not controlled with an appropriate
dose, testing for factor VIII inhibitor presence should be performed. In
patients with high levels of inhibitor, factor VIII therapy may not be
effective and other therapeutic options should be considered. Management of
such patients should be directed by physicians with experience in the care of
haemophilia and factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central venous
access device (CVAD) is required, risk of CVAD&#8209;related complications
including local infections, bacteremia and catheter site thrombosis should be
considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and
batch number of the product are recorded </span><span lang=EN-GB>in order to
maintain a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal
reproduction studies have not been conducted with factor VIII. Based on the
rare occurrence of haemophilia A in women, experience regarding the use of
factor VIII during pregnancy and breast&#8209;feeding is not available. Therefore,
factor VIII should be used during pregnancy and breast-feeding only if clearly
indicated.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE has no influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Summary of the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE reporting
in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The ADRs
that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills,
flushing, generalised urticaria, headache, hives, hypotension, lethargy,
nausea, restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster
protein with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A
treated with factor VIII, including with ADVATE. If such inhibitors occur, the
condition will manifest itself as an insufficient clinical response. In such
cases, it is recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical
trials and from spontaneous reporting. The table is according to the MedDRA
system organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following
convention: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to
&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000),
not known (cannot be estimated from the available data). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injury, poisoning and procedural complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>a) Calculated based on total number of patients
who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred
in one patient during continuous infusion of ADVATE following surgery (postoperative
days&nbsp;10&#8209;14). Haemostasis was maintained at all times during this period
and both plasma factor VIII levels and clearance rates returned to appropriate
levels by postoperative day&nbsp;15. Factor VIII inhibitor assays performed
after completion of continuous infusion and at study termination were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>c) ADR explained in the section below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs =
previously-treated patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically significant
upward trend in titres,&nbsp;4&nbsp;displayed sustained peaks or transient spikes
and one patient had both but no clinical symptoms. Of the&nbsp;229&nbsp;treated
patients who were assessed for antibodies to murine IgG,&nbsp;10&nbsp;showed a
statistically significant upward trend,&nbsp;2&nbsp;displayed a sustained peak
or transient spike and one patient had both. Four of these patients reported
isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil
counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type reactions
include anaphylaxis and have been manifested by dizziness, paresthesias, rash,
flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
ADRs were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No symptoms of
overdose with recombinant coagulation factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pharmacotherapeutic group: antihaemorrhagics, blood coagulation
factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The factor
VIII/von Willebrand Factor complex consists of two molecules (factor VIII and
von Willebrand Factor) with different physiological functions. ADVATE contains
recombinant coagulation factor VIII (octocog alfa), a glycoprotein that is biologically
equivalent to the factor VIII glycoprotein found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient,
octocog alfa binds to endogenous von Willebrand Factor in the patients
circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,
accelerating the conversion of Factor X to activated Factor X. Activated Factor
X converts prothrombin to thrombin. Thrombin then converts fibrinogen into
fibrin and a clot can be formed. Haemophilia A is a sex&#8209;linked hereditary
disorder of blood coagulation due to decreased levels of factor VIII activity
and results in profuse bleeding into joints, muscles or internal organs, either
spontaneously or as a result of accidental or surgical trauma. The plasma
levels of factor VIII are increased by replacement therapy, thereby enabling a
temporary correction of the factor VIII deficiency and correction of the
bleeding tendency.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done for&nbsp;30&nbsp;paediatric
subjects on ITI (in study&nbsp;060703). A non-interventional prospective
registry (PASS-INT-004) documented ITI in 44 paediatric and adult subjects of
whom 36 completed ITI therapy. Data show that immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23)
with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a&nbsp;specific
formula) was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated
patients with severe to moderately severe haemophilia A (baseline factor VIII &#8804;&nbsp;2%).
The analysis of plasma samples was conducted in a central laboratory using a
one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1&nbsp;month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>Adjusted
  Incremental Recovery at Cmax (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR style='font-size:10.0pt'>Maximum Plasma Concentration Post Infusion
  (IU/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety and haemostatic efficacy of ADVATE in the paediatric
population are similar to that of adult patients. Adjusted recovery and
terminal half&#8209;life (t<sub></sub>) was approximately&nbsp;20% lower in
young children (less than&nbsp;6&nbsp;years of age) than in adults, which may
be due in part to the known higher plasma volume per kilogram body weight in
younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetic
data with ADVATE on previously untreated patients are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months
storage at room temperature should be recorded on the product carton. The
product may not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Both the powder vial and the vial containing 5&nbsp;ml solvent are
of type I glass closed with chlorobutyl rubber stoppers. The product is
provided in one of the following configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;5&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 5 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be administered
intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Reconstitution
with the BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take both the ADVATE powder and solvent vials from the
refrigerator and let them reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>5. Open the package of BaxJect&nbsp;II
device by peeling away the paper lid without touching the inside (Fig. a). Do
not remove the device from the package. Do not use if the BAXJECT II device,
its sterile barrier system or its packaging is damaged or shows any sign of
deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder
stopper. The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image009.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the </span><span
lang=EN-GB>BAXJECT&nbsp;III system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for
reconstitution) from the refrigerator and let it reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass
through the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image010.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image011.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image012.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral medicinal
products should be inspected for particulate matter prior to administration,
whenever solution and container permit. Only a clear and colourless solution
should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4. Attach a butterfly
needle to the syringe. Inject intravenously. The solution should be
administered slowly, at a rate as determined by the patients comfort level,
not to exceed&nbsp;10&nbsp;ml per minute. The pulse rate should be determined
before and during administration of ADVATE. Should a significant increase
occur, reducing the rate of administration or temporarily interrupting the
injection usually allows the symptoms to disappear promptly (see
sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>EU/1/03/271/004</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>EU/1/03/271/014</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Date of first authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000&nbsp;IU
powder and solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial contains
nominally&nbsp;2000&nbsp;IU human coagulation factor VIII (rDNA), octocog alfa.
ADVATE contains approximately&nbsp;400&nbsp;IU per ml of human coagulation
factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is
approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of
units of factor VIII is expressed in International Units (IU), which are
related to the WHO standard for factor VIII products. Factor VIII activity in
plasma is expressed either as a percentage (relative to normal human plasma) or
in IUs (relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII
activity is equivalent to that quantity of factor VIII in one ml of normal
human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the following
formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Required units
(IU)&nbsp;=&nbsp;body weight (kg) x desired factor VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life threatening
  haemorrhages.</span></p>
  </td>
  <td width="26%" valign=top style='width:26.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or
  more until pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours
  for patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) until adequate wound healing, then continue
  therapy for at least another&nbsp;7&nbsp;days to maintain a factor VIII
  activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the individual
case. Under certain circumstances (e.g. presence of a low&#8209;titre inhibitor),
doses larger than those calculated using the formula may be necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is
advised to guide the dose to be administered and the frequency of repeated
injections. In the case of major surgical interventions in particular, precise
monitoring of the substitution therapy by means of plasma factor VIII activity
assay is indispensable. Individual patients may vary in their response to
factor VIII, achieving different levels of <i>in vivo</i> recovery and
demonstrating different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU
of factor VIII per kg body weight 3 to 4 times weekly are recommended for
prophylactic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the
medicinal product before </span><span lang=EN-GB>administration, see
section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients </span><span lang=EN-GB>listed
in section 6.1 </span><span lang=EN-GB>or to mouse or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms
of hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised urticaria,
tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of
shock, standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more
than&nbsp;100&nbsp;exposure days who have a previous history of inhibitor
development. Therefore, it is recommended to monitor all patients carefully for
inhibitor occurrence following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical observations
and laboratory tests. If the expected factor VIII activity plasma levels are
not attained, or if bleeding is not controlled with an appropriate dose,
testing for factor VIII inhibitor presence should be performed. In patients
with high levels of inhibitor, factor VIII therapy may not be effective and
other therapeutic options should be considered. Management of such patients
should be directed by physicians with experience in the care of haemophilia and
factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central venous
access device (CVAD) is required, risk of CVAD&#8209;related complications
including local infections, bacteremia and catheter site thrombosis should be
considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and
batch number of the product are recorded </span><span lang=EN-GB>in order to
maintain a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction studies
have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal
reproduction studies have not been conducted with factor VIII. Based on the
rare occurrence of haemophilia A in women, experience regarding the use of
factor VIII during pregnancy and breast&#8209;feeding is not available. Therefore,
factor VIII should be used during pregnancy and breast-feeding only if clearly
indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE</span><span
lang=EN-GB> has no influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Summary of
the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE reporting
in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The ADRs
that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills, flushing,
generalised urticaria, headache, hives, hypotension, lethargy, nausea,
restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster
protein with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A
treated with factor VIII, including with ADVATE. If such inhibitors occur, the
condition will manifest itself as an insufficient clinical response. In such
cases, it is recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical
trials and from spontaneous reporting. The table is according to the MedDRA
system organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following
convention: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to
&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000),
not known (cannot be estimated from the available data). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injury, poisoning and procedural complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>a) Calculated based on total number of patients
who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred
in one patient during continuous infusion of ADVATE following surgery (postoperative
days&nbsp;10&#8209;14). Haemostasis was maintained at all times during this period
and both plasma factor VIII levels and clearance rates returned to appropriate
levels by postoperative day&nbsp;15. Factor VIII inhibitor assays performed
after completion of continuous infusion and at study termination were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>c) ADR explained in the section
below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs =
previously-treated patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically significant
upward trend in titres, 4&nbsp;displayed sustained peaks or transient spikes
and one patient had both but no clinical symptoms. Of the&nbsp;229&nbsp;treated
patients who were assessed for antibodies to murine IgG,&nbsp;10&nbsp;showed a
statistically significant upward trend,&nbsp;2&nbsp;displayed a sustained peak
or transient spike and one patient had both. Four of these patients reported
isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil
counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type reactions
include anaphylaxis and have been manifested by dizziness, paresthesias, rash,
flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs), and
catheter&#8209;related complications, no age&#8209;specific differences in ADRs
were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No symptoms of
overdose with recombinant coagulation factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The factor
VIII/von Willebrand Factor complex consists of two molecules (factor VIII and
von Willebrand Factor) with different physiological functions. ADVATE contains
recombinant coagulation factor VIII (octocog alfa), a glycoprotein that is biologically
equivalent to the factor VIII glycoprotein found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient,
octocog alfa binds to endogenous von Willebrand Factor in the patients
circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,
accelerating the conversion of Factor X to activated Factor X. Activated Factor
X converts prothrombin to thrombin. Thrombin then converts fibrinogen into
fibrin and a clot can be formed. Haemophilia A is a sex&#8209;linked hereditary
disorder of blood coagulation due to decreased levels of factor VIII activity and
results in profuse bleeding into joints, muscles or internal organs, either spontaneously
or as a result of accidental or surgical trauma. The plasma levels of factor
VIII are increased by replacement therapy, thereby enabling a temporary
correction of the factor VIII deficiency and correction of the bleeding tendency.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a&nbsp;sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done for&nbsp;30&nbsp;<span
style='letter-spacing:-.15pt'>paediatric</span> subjects on ITI (in study&nbsp;060703).
A non-interventional prospective registry (PASS-INT-004) documented ITI in 44
paediatric and adult subjects of whom 36 completed ITI therapy. Data show that
immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23)
with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a specific
formula) was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII deficiency)&quot;.
(see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated
patients with severe to moderately severe haemophilia A (baseline factor VIII &#8804;&nbsp;2%).
The analysis of plasma samples was conducted in a central laboratory using a
one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>Adjusted
  Incremental Recovery at Cmax (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR style='font-size:10.0pt'>Maximum Plasma Concentration Post Infusion
  (IU/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety and haemostatic efficacy of ADVATE in the paediatric
population are similar to that of adult patients. Adjusted recovery and
terminal half&#8209;life (t<sub></sub>) was approximately&nbsp;20% lower in
young children (less than&nbsp;6&nbsp;years of age) than in adults, which may
be due in part to the known higher plasma volume per kilogram body weight in
younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetic
data with ADVATE on previously untreated patients are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months
storage at room temperature should be recorded on the product carton. The
product may not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Both the powder vial and the vial containing 5&nbsp;ml solvent are
of type I glass closed with chlorobutyl rubber stoppers. The product is
provided in one of the following configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;5&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 5 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be
administered intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Reconstitution
with the BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take both the ADVATE powder and solvent vials from the
refrigerator and let them reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder
stopper. The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image009.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the </span><span
lang=EN-GB>BAXJECT&nbsp;III system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for
reconstitution) from the refrigerator and let it reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass
through the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image010.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image011.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image012.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral
medicinal products should be inspected for particulate matter prior to
administration, whenever solution and container permit. Only a clear and
colourless solution should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4. Attach a butterfly
needle to the syringe. Inject intravenously. The solution should be
administered slowly, at a rate as determined by the patients comfort level,
not to exceed&nbsp;10&nbsp;ml per minute. The pulse rate should be determined
before and during administration of ADVATE. Should a significant increase
occur, reducing the rate of administration or temporarily interrupting the
injection usually allows the symptoms to disappear promptly (see
sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/005</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/015</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed information
on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product is
available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>ADVATE&nbsp;3000&nbsp;IU powder and solvent for
solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains nominally&nbsp;3000&nbsp;IU human coagulation factor VIII (rDNA),
octocog alfa. ADVATE contains approximately&nbsp;600&nbsp;IU per ml of human coagulation
factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is
approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and solvent
for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of units
of factor VIII is expressed in International Units (IU), which are related to
the WHO standard for factor VIII products. Factor VIII activity in plasma is
expressed either as a percentage (relative to normal human plasma) or in IUs
(relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII activity
is equivalent to that quantity of factor VIII in one ml of normal human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the
following formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Required units (IU)&nbsp;=&nbsp;body weight (kg) x desired factor
VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width=158 valign=top style='width:118.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width=253 valign=top style='width:189.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life
  threatening haemorrhages.</span></p>
  </td>
  <td width=158 valign=top style='width:118.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width=253 valign=top style='width:189.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or
  more until pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours
  for patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width=208 valign=top style='width:155.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=158 valign=top style='width:118.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width=253 valign=top style='width:189.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) until adequate wound healing, then
  continue therapy for at least another&nbsp;7&nbsp;days to maintain a factor
  VIII activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is
advised to guide the dose to be administered and the frequency of repeated
injections. In the case of major surgical interventions in particular, precise
monitoring of the substitution therapy by means of plasma factor VIII activity
assay is indispensable. Individual patients may vary in their response to
factor VIII, achieving different levels of <i>in vivo</i> recovery and
demonstrating different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU
of factor VIII per kg body weight 3 to 4 times weekly are recommended for
prophylactic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the
medicinal product before </span><span lang=EN-GB>administration, see
section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients </span><span lang=EN-GB>listed
in section 6.1 </span><span lang=EN-GB>or to mouse or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms
of hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised
urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of
shock, standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more
than&nbsp;100&nbsp;exposure days who have a previous history of inhibitor
development. Therefore, it is recommended to monitor all patients carefully for
inhibitor occurrence following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical
observations and laboratory tests. If the expected factor VIII activity plasma
levels are not attained, or if bleeding is not controlled with an appropriate
dose, testing for factor VIII inhibitor presence should be performed. In
patients with high levels of inhibitor, factor VIII therapy may not be effective
and other therapeutic options should be considered. Management of such patients
should be directed by physicians with experience in the care of haemophilia and
factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central
venous access device (CVAD) is required, risk of CVAD&#8209;related
complications including local infections, bacteremia and catheter site
thrombosis should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly recommended
that every time ADVATE is administered to a patient, the name and batch number
of the product are recorded </span><span lang=EN-GB>in order to maintain a link
between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal
reproduction studies have not been conducted with factor VIII. Based on the
rare occurrence of haemophilia A in women, experience regarding the use of
factor VIII during pregnancy and breast&#8209;feeding is not available.
Therefore, factor VIII should be used during pregnancy and breast-feeding only
if clearly indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE</span><span lang=EN-GB> has no influence on the ability to
drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Summary of the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE
reporting in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The
ADRs that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills,
flushing, generalised urticaria, headache, hives, hypotension, lethargy,
nausea, restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster
protein with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A
treated with factor VIII, including with ADVATE. If such inhibitors occur, the
condition will manifest itself as an insufficient clinical response. In such
cases, it is recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical
trials and from spontaneous reporting. The table is according to the MedDRA
system organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following
convention: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to
&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000),
not known (cannot be estimated from the available data). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injury, poisoning and procedural complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>a) Calculated based on total number of patients
who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred
in one patient during continuous infusion of ADVATE following surgery
(postoperative days&nbsp;10&#8209;14). Haemostasis was maintained at all times
during this period and both plasma factor VIII levels and clearance rates
returned to appropriate levels by postoperative day&nbsp;15. Factor VIII inhibitor
assays performed after completion of continuous infusion and at study
termination were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>c) ADR explained in the section below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs = previously-treated
patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically
significant upward trend in titres,&nbsp;4&nbsp;displayed sustained peaks or
transient spikes and one patient had both but no clinical symptoms. Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to murine
IgG,&nbsp;10&nbsp;showed a statistically significant upward trend,&nbsp;2&nbsp;displayed
a sustained peak or transient spike and one patient had both. Four of these
patients reported isolated events of urticaria, pruritus, rash, and slightly
elevated eosinophil counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
reactions include anaphylaxis and have been manifested by dizziness,
paresthesias, rash, flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
ADRs were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No symptoms of
overdose with recombinant coagulation factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The factor
VIII/von Willebrand Factor complex consists of two molecules (factor VIII and
von Willebrand Factor) with different physiological functions. ADVATE contains
recombinant coagulation factor VIII (octocog alfa), a glycoprotein that is biologically
equivalent to the factor VIII glycoprotein found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient, octocog
alfa binds to endogenous von Willebrand Factor in the patients circulation.
Activated factor VIII acts as a Cofactor for activated Factor IX, accelerating
the conversion of Factor X to activated Factor X. Activated Factor X converts
prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin and a
clot can be formed. Haemophilia A is a sex&#8209;linked hereditary disorder of
blood coagulation due to decreased levels of factor VIII activity and results
in profuse bleeding into joints, muscles or internal organs, either spontaneously
or as a result of accidental or surgical trauma. The plasma levels of factor
VIII are increased by replacement therapy, thereby enabling a temporary
correction of the factor VIII deficiency and correction of the bleeding
tendency.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done for&nbsp;30&nbsp;<span
style='letter-spacing:-.15pt'>paediatric</span> subjects on ITI (in study&nbsp;060703).
A non-interventional prospective registry (PASS-INT-004) documented ITI in 44
paediatric and adult subjects of whom 36 completed ITI therapy. Data show that
immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23)
with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a specific
formula) was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated
patients with severe to moderately severe haemophilia A (baseline factor VIII &#8804;&nbsp;2%).
The analysis of plasma samples was conducted in a central laboratory using a
one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="19%" valign=top style='width:19.14%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>Adjusted
  Incremental Recovery at Cmax (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR style='font-size:10.0pt'>Maximum Plasma Concentration Post Infusion
  (IU/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.14%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety and haemostatic efficacy of ADVATE in the paediatric
population are similar to that of adult patients. Adjusted recovery and
terminal half&#8209;life (t<sub></sub>) was approximately&nbsp;20% lower in
young children (less than&nbsp;6&nbsp;years of age) than in adults, which may
be due in part to the known higher plasma volume per kilogram body weight in
younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacokinetic data with ADVATE on previously untreated patients
are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months
storage at room temperature should be recorded on the product carton. The
product may not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Both the powder vial and the vial containing 5&nbsp;ml solvent are
of type I glass closed with chlorobutyl rubber stoppers. The product is
provided in one of the following configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;5&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 5 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be
administered intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the
BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take both the ADVATE powder and solvent vials from the
refrigerator and let them reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder
stopper. The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image009.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the </span><span
lang=EN-GB>BAXJECT&nbsp;III system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for
reconstitution) from the refrigerator and let it reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass
through the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image011.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image012.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral
medicinal products should be inspected for particulate matter prior to
administration, whenever solution and container permit. Only a clear and
colourless solution should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4. Attach a butterfly
needle to the syringe. Inject intravenously. The solution should be
administered slowly, at a rate as determined by the patients comfort level,
not to exceed&nbsp;10&nbsp;ml per minute. The pulse rate should be determined
before and during administration of ADVATE. Should a significant increase
occur, reducing the rate of administration or temporarily interrupting the
injection usually allows the symptoms to disappear promptly (see
sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/006</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/016</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU powder
and solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains nominally&nbsp;250&nbsp;IU human coagulation factor VIII (rDNA),
octocog alfa. ADVATE contains approximately&nbsp;125&nbsp;IU per ml of human
coagulation factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is
approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and solvent
for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of
units of factor VIII is expressed in International Units (IU), which are
related to the WHO standard for factor VIII products. Factor VIII activity in
plasma is expressed either as a percentage (relative to normal human plasma) or
in IUs (relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII activity
is equivalent to that quantity of factor VIII in one ml of normal human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the
following formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Required units (IU)&nbsp;=&nbsp;body weight (kg) x desired factor
VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="25%" valign=top style='width:25.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life&#8209;threatening
  haemorrhages.</span></p>
  </td>
  <td width="25%" valign=top style='width:25.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours
  (8&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6)
  for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more until pain and acute disability
  are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;12&nbsp;hours for patients under the age of&nbsp;6) until
  threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6) until
  adequate wound healing, then continue therapy for at least
  another&nbsp;7&nbsp;days to maintain a factor VIII activity of&nbsp;30%
  to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is
advised to guide the dose to be administered and the frequency of repeated injections.
In the case of major surgical interventions in particular, precise monitoring
of the substitution therapy by means of plasma factor VIII activity assay is
indispensable. Individual patients may vary in their response to factor VIII,
achieving different levels of <i>in vivo</i> recovery and demonstrating different
half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU
of factor VIII per kg body weight 3 to 4 times weekly are recommended for
prophylactic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the medicinal
product before </span><span lang=EN-GB>administration, see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients </span><span lang=EN-GB>listed
in section 6.1 </span><span lang=EN-GB>or to mouse or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms
of hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised
urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of shock,
standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
decrease in injection volume for ADVATE reconstituted in&nbsp;2&nbsp;ml sterilised
water for injections, if hypersensitivity reactions occur there is less time to
react by stopping the injection. Therefore, caution is advised during injection
of ADVATE reconstituted in&nbsp;2&nbsp;ml sterilised water for injections,
especially in children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more than&nbsp;100&nbsp;exposure
days who have a previous history of inhibitor development. Therefore, it is
recommended to monitor all patients carefully for inhibitor occurrence
following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical
observations and laboratory tests. If the expected factor VIII activity plasma
levels are not attained, or if bleeding is not controlled with an appropriate
dose, testing for factor VIII inhibitor presence should be performed. In patients
with high levels of inhibitor, factor VIII therapy may not be effective and
other therapeutic options should be considered. Management of such patients
should be directed by physicians with experience in the care of haemophilia and
factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Misapplication of ADVATE</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For ADVATE reconstituted
with&nbsp;2&nbsp;ml sterilised water for injections, misapplication (intra&#8209;arterially
or paravenously) may lead to mild, short term injection site reactions, such as
bruising and erythema.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central
venous access device (CVAD) is required, risk of CVAD&#8209;related
complications including local infections, bacteremia and catheter site thrombosis
should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and
batch number of the product are recorded </span><span lang=EN-GB>in order to maintain
a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 </span></b><b><span
lang=EN-GB>Fertility, </span></b><b><span lang=EN-GB>pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Animal reproduction studies have not been conducted with factor
VIII. Based on the rare</span><span class=MsoCommentReference><span lang=EN-GB
style='font-size:8.0pt'> </span></span><span lang=EN-GB>occurrence of
haemophilia A in women, experience regarding the use of factor VIII during
pregnancy and breast&#8209;feeding is not available. Therefore, factor VIII should
be used during pregnancy and breast-feeding only if clearly indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE</span><span
lang=EN-GB> has no influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Summary of the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE
reporting in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The
ADRs that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills,
flushing, generalised urticaria, headache, hives, hypotension, lethargy,
nausea, restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster protein
with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A
treated with factor VIII, including with ADVATE. If such inhibitors occur, the
condition will manifest itself as an insufficient clinical response. In such cases,
it is recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical trials
and from spontaneous reporting. The table is according to the MedDRA system
organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following
convention: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to
&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare
(&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing
seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Injury, poisoning and procedural complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>a) Calculated based on
total number of patients who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred in
one patient during continuous infusion of ADVATE following surgery
(postoperative days&nbsp;10&#8209;14). Haemostasis was maintained at all times
during this period and both plasma factor VIII levels and clearance rates
returned to appropriate levels by postoperative day&nbsp;15. Factor VIII
inhibitor assays performed after completion of continuous infusion and at study
termination were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>c) ADR explained in the section
below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs = previously-treated
patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically
significant upward trend in titres, 4&nbsp;displayed sustained peaks or
transient spikes and one patient had both but no clinical symptoms. Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to murine
IgG,&nbsp;10&nbsp;showed a statistically significant upward trend,&nbsp;2&nbsp;displayed
a sustained peak or transient spike and one patient had both. Four of these
patients reported isolated events of urticaria, pruritus, rash, and slightly elevated
eosinophil counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
reactions include anaphylaxis and have been manifested by dizziness,
paresthesias, rash, flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs), and
catheter&#8209;related complications, no age&#8209;specific differences in ADRs
were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting suspected
adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No symptoms of
overdose with recombinant coagulation factor VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1 Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The factor VIII/von Willebrand Factor complex consists of two
molecules (factor VIII and von Willebrand Factor) with different physiological
functions. ADVATE contains recombinant coagulation factor VIII (octocog alfa),
a glycoprotein that is biologically equivalent to the factor VIII glycoprotein
found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient, octocog
alfa binds to endogenous von Willebrand Factor in the patients circulation.
Activated factor VIII acts as a Cofactor for activated Factor IX, accelerating
the conversion of Factor X to activated Factor X. Activated Factor X converts
prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin and a
clot can be formed. Haemophilia A is a sex&#8209;linked hereditary disorder of
blood coagulation due to decreased levels of factor VIII activity and results
in profuse bleeding into joints, muscles or internal organs, either spontaneously
or as a result of accidental or surgical trauma. The plasma levels of factor VIII
are increased by replacement therapy, thereby enabling a temporary correction
of the factor VIII deficiency and correction of the bleeding tendency.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done for&nbsp;30&nbsp;<span
style='letter-spacing:-.15pt'>paediatric</span> subjects on ITI (in study&nbsp;060703).
A non-interventional prospective registry (PASS-INT-004) documented ITI in 44
paediatric and adult subjects of whom 36 completed ITI therapy. Data show that
immune tolerance may be achieved. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23)
with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a specific
formula) was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All pharmacokinetic
studies with ADVATE were conducted in previously treated patients with severe
to moderately severe haemophilia A (baseline factor VIII &#8804;&nbsp;2%). The
analysis of plasma samples was conducted in a central laboratory using a one&#8209;stage
clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="20%" valign=top style='width:20.84%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.98%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.24%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="20%" valign=top style='width:20.84%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="13%" valign=top style='width:13.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.84%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Adjusted Incremental Recovery at Cmax
  (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="13%" valign=top style='width:13.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.84%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="13%" valign=top style='width:13.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.84%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=FR style='font-size:10.0pt'>Maximum Plasma Concentration
  Post Infusion (IU/dl)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="13%" valign=top style='width:13.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.84%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="13%" valign=top style='width:13.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.84%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="14%" valign=top style='width:14.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="13%" valign=top style='width:13.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.84%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="14%" valign=top style='width:14.98%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="13%" valign=top style='width:13.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
haemostatic efficacy of ADVATE in the paediatric population are similar to that
of adult patients. Adjusted recovery and terminal half&#8209;life (t<sub></sub>)
was approximately&nbsp;20% lower in young children (less than&nbsp;6&nbsp;years
of age) than in adults, which may be due in part to the known higher plasma
volume per kilogram body weight in younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetic
data with ADVATE on previously untreated patients are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A local
tolerance study in rabbits showed that ADVATE reconstituted with&nbsp;2&nbsp;ml
of sterilised water for injections is well tolerated after intravenous administration.
Slight transient reddening at the administration site was observed after
intraarterial application and after paravenous administration. However, no
correlating adverse histopathological changes could be observed indicating a
transient nature of this finding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months
storage at room temperature should be recorded on the product carton. The
product may not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Both the powder
vial and the vial containing 2&nbsp;ml solvent are of type I glass closed with
chlorobutyl rubber stoppers. The product is provided in one of the following
configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack contains
a powder vial, a vial containing&nbsp;2&nbsp;ml solvent and a device for
reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 2 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be
administered intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Reconstitution
with the BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take both the ADVATE powder and solvent vials from the
refrigerator and let them reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be used.
With <span style='text-transform:uppercase'>Baxject&nbsp;II</span> attached to
the solvent vial, invert the system so that the solvent vial is on top of the
device. Insert the white plastic spike through the ADVATE powder stopper. The
vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image013.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the </span><span
lang=EN-GB>BAXJECT&nbsp;III system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for
reconstitution) from the refrigerator and let it reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass through
the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image003.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image004.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral
medicinal products should be inspected for particulate matter prior to
administration, whenever solution and container permit. Only a clear and
colourless solution should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Attach a butterfly needle to the syringe.
Inject intravenously. The solution should be administered slowly, at a rate as
determined by the patients comfort level, not to exceed&nbsp;10&nbsp;ml per
minute. The pulse rate should be determined before and during administration of
ADVATE. Should a significant increase occur, reducing the rate of
administration or temporarily interrupting the injection usually allows the
symptoms to disappear promptly (see sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING AUTHORISATION
HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/007</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/017</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Date of first authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU powder and solvent for
solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains nominally&nbsp;500&nbsp;IU human coagulation factor VIII (rDNA),
octocog alfa. ADVATE contains approximately&nbsp;250&nbsp;IU per ml of human coagulation
factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of
units of factor VIII is expressed in International Units (IU), which are
related to the WHO standard for factor VIII products. Factor VIII activity in
plasma is expressed either as a percentage (relative to normal human plasma) or
in IUs (relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII
activity is equivalent to that quantity of factor VIII in one ml of normal
human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the
following formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Required units (IU)&nbsp;=&nbsp;body weight (kg) x desired factor
VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life
  threatening haemorrhages.</span></p>
  </td>
  <td width="26%" valign=top style='width:26.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours
  (8&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6)
  for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more until pain and acute disability are
  resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;12&nbsp;hours for patients under the age of&nbsp;6) until
  threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6) until
  adequate wound healing, then continue therapy for at least another&nbsp;7&nbsp;days
  to maintain a factor VIII activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is
advised to guide the dose to be administered and the frequency of repeated
injections. In the case of major surgical interventions in particular, precise
monitoring of the substitution therapy by means of plasma factor VIII activity
assay is indispensable. Individual patients may vary in their response to
factor VIII, achieving different levels of <i>in vivo</i> recovery and demonstrating
different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand treatment
dosing in paediatric patients (0 to 18 years of age) does not differ from adult
patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU of factor
VIII per kg body weight 3 to 4 times weekly are recommended for prophylactic
therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the
medicinal product before </span><span lang=EN-GB>administration, see
section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients </span><span lang=EN-GB>listed
in section 6.1 </span><span lang=EN-GB>or to mouse or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type hypersensitivity
reactions, including anaphylaxis, have been reported with ADVATE. The product
contains traces of mouse and hamster proteins. If symptoms of hypersensitivity
occur, patients should be advised to discontinue use of the product immediately
and contact their physician. Patients should be informed of the early signs of
hypersensitivity reactions including hives, generalised urticaria, tightness of
the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of shock,
standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the decrease
in injection volume for ADVATE reconstituted in&nbsp;2&nbsp;ml sterilised water
for injections, if hypersensitivity reactions occur there is less time to react
by stopping the injection. Therefore, caution is advised during injection of
ADVATE reconstituted in&nbsp;2&nbsp;ml sterilised water for injections, especially
in children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more
than&nbsp;100&nbsp;exposure days who have a previous history of inhibitor
development. Therefore, it is recommended to monitor all patients carefully for
inhibitor occurrence following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical
observations and laboratory tests. If the expected factor VIII activity plasma
levels are not attained, or if bleeding is not controlled with an appropriate
dose, testing for factor VIII inhibitor presence should be performed. In
patients with high levels of inhibitor, factor VIII therapy may not be
effective and other therapeutic options should be considered. Management of
such patients should be directed by physicians with experience in the care of
haemophilia and factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Misapplication of ADVATE</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For ADVATE reconstituted
with&nbsp;2&nbsp;ml sterilised water for injections, misapplication (intra&#8209;arterially
or paravenously) may lead to mild, short term injection site reactions, such as
bruising and erythema.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central
venous access device (CVAD) is required, risk of CVAD&#8209;related complications
including local infections, bacteremia and catheter site thrombosis should be
considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and
batch number of the product are recorded </span><span lang=EN-GB>in order to maintain
a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal reproduction
studies have not been conducted with factor VIII. Based on the rare occurrence
of haemophilia A in women, experience regarding the use of factor VIII during
pregnancy and breast&#8209;feeding is not available. Therefore, factor VIII
should be used during pregnancy and breast-feeding only if clearly indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE has no
influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Summary of
the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE
reporting in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The
ADRs that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills,
flushing, generalised urticaria, headache, hives, hypotension, lethargy,
nausea, restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster
protein with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of neutralising
antibodies (inhibitors) may occur in patients with haemophilia A treated with
factor VIII, including with ADVATE. If such inhibitors occur, the condition
will manifest itself as an insufficient clinical response. In such cases, it is
recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical
trials and from spontaneous reporting. The table is according to the MedDRA system
organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following
convention: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to
&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare
(&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of
decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Injury, poisoning and procedural
  complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>a) Calculated based on
total number of patients who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred
in one patient during continuous infusion of ADVATE following surgery
(postoperative days&nbsp;10&#8209;14). Haemostasis was maintained at all times
during this period and both plasma factor VIII levels and clearance rates returned
to appropriate levels by postoperative day&nbsp;15. Factor VIII inhibitor
assays performed after completion of continuous infusion and at study termination
were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>c) ADR explained in the section
below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs =
previously-treated patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically
significant upward trend in titres, 4&nbsp;displayed sustained peaks or transient
spikes and one patient had both but no clinical symptoms. Of the&nbsp;229&nbsp;treated
patients who were assessed for antibodies to murine IgG,&nbsp;10&nbsp;showed a
statistically significant upward trend,&nbsp;2&nbsp;displayed a sustained peak
or transient spike and one patient had both. Four of these patients reported
isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil
counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
reactions include anaphylaxis and have been manifested by dizziness,
paresthesias, rash, flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
ADRs were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No symptoms of
overdose with recombinant coagulation factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The factor VIII/von Willebrand Factor complex consists of two
molecules (factor VIII and von Willebrand Factor) with different physiological
functions. ADVATE contains recombinant coagulation factor VIII (octocog alfa),
a glycoprotein that is biologically equivalent to the factor VIII glycoprotein
found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient,
octocog alfa binds to endogenous von Willebrand Factor in the patients
circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,
accelerating the conversion of Factor X to activated Factor X. Activated Factor
X converts prothrombin to thrombin. Thrombin then converts fibrinogen into
fibrin and a clot can be formed. Haemophilia A is a sex&#8209;linked hereditary
disorder of blood coagulation due to decreased levels of factor VIII activity
and results in profuse bleeding into joints, muscles or internal organs, either
spontaneously or as a result of accidental or surgical trauma. The plasma
levels of factor VIII are increased by replacement therapy, thereby enabling a
temporary correction of the factor VIII deficiency and correction of the
bleeding tendency.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a&nbsp;sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done
for&nbsp;30&nbsp;<span style='letter-spacing:-.15pt'>paediatric</span> subjects
on ITI (in study&nbsp;060703). A non-interventional prospective registry
(PASS-INT-004) documented ITI in 44 paediatric and adult subjects of whom 36
completed ITI therapy. Data show that immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23)
with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a specific
formula) was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated
patients with severe to moderately severe haemophilia A (baseline factor VIII
&#8804;&nbsp;2%). The analysis of plasma samples was conducted in a central
laboratory using a one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Adjusted Incremental Recovery at Cmax
  (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=FR style='font-size:10.0pt'>Maximum Plasma
  Concentration Post Infusion (IU/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
haemostatic efficacy of ADVATE in the paediatric population are similar to that
of adult patients. Adjusted recovery and terminal half&#8209;life (t<sub></sub>)
was approximately&nbsp;20% lower in young children (less than&nbsp;6&nbsp;years
of age) than in adults, which may be due in part to the known higher plasma
volume per kilogram body weight in younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacokinetic
data with ADVATE on previously untreated patients are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety pharmacology,
acute toxicology, repeated dose toxicity, local toxicity and genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A local
tolerance study in rabbits showed that ADVATE reconstituted with&nbsp;2&nbsp;ml
of sterilised water for injections is well tolerated after intravenous
administration. Slight transient reddening at the administration site was
observed after intraarterial application and after paravenous administration.
However, no correlating adverse histopathological changes could be observed
indicating a transient nature of this finding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months
storage at room temperature should be recorded on the product carton. The
product may not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Both the powder
vial and the vial containing 2&nbsp;ml solvent are of type I glass closed with
chlorobutyl rubber stoppers. The product is provided in one of the following
configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;2&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 2 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be
administered intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Reconstitution
with the BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1. If the product is
still stored in a refrigerator, take both the ADVATE powder and solvent vials
from the refrigerator and let them reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder
stopper. The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image013.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the </span><span
lang=EN-GB>BAXJECT&nbsp;III system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a refrigerator,
take <span style='color:black'>the</span> sealed blister (contains powder and
solvent vials preassembled with the system for reconstitution) from the refrigerator
and let it reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass
through the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image003.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image004.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral
medicinal products should be inspected for particulate matter prior to
administration, whenever solution and container permit. Only a clear and
colourless solution should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Attach a butterfly needle to the syringe.
Inject intravenously. The solution should be administered slowly, at a rate as
determined by the patients comfort level, not to exceed&nbsp;10&nbsp;ml per
minute. The pulse rate should be determined before and during administration of
ADVATE. Should a significant increase occur, reducing the rate of
administration or temporarily interrupting the injection usually allows the
symptoms to disappear promptly (see sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/008</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/018</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST AUTHORISATION/RENEWAL
OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Date of first
authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU powder
and solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains nominally&nbsp;1000&nbsp;IU human coagulation factor VIII (rDNA),
octocog alfa. ADVATE contains approximately&nbsp;500&nbsp;IU per ml of human
coagulation factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is
approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared without
the addition of any (exogenous) human&#8209; or animal&#8209;derived protein in
the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>For the full list of
excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment
of haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of units
of factor VIII is expressed in International Units (IU), which are related to
the WHO standard for factor VIII products. Factor VIII activity in plasma is
expressed either as a percentage (relative to normal human plasma) or in IUs
(relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII
activity is equivalent to that quantity of factor VIII in one ml of normal
human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the
following formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Required units
(IU)&nbsp;=&nbsp;body weight (kg) x desired factor VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life
  threatening haemorrhages.</span></p>
  </td>
  <td width="26%" valign=top style='width:26.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours
  (8&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6) for at
  least&nbsp;1&nbsp;day, until the bleeding episode, as indicated by pain, is
  resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours
  (8&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6)
  for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more until pain and acute disability
  are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours for
  patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.36%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6) until
  adequate wound healing, then continue therapy for at least another&nbsp;7&nbsp;days
  to maintain a factor VIII activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the course
of treatment, appropriate determination of plasma factor VIII levels is advised
to guide the dose to be administered and the frequency of repeated injections.
In the case of major surgical interventions in particular, precise monitoring
of the substitution therapy by means of plasma factor VIII activity assay is
indispensable. Individual patients may vary in their response to factor VIII,
achieving different levels of <i>in vivo</i> recovery and demonstrating
different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual
doses are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU
of factor VIII per kg body weight 3 to 4 times weekly are recommended for prophylactic
therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the
medicinal product before </span><span lang=EN-GB>administration, see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Hypersensitivity to the active
substance or to any of the excipients </span><span lang=EN-GB>listed in section
6.1 </span><span lang=EN-GB>or to mouse or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms
of hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised
urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of
shock, standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
decrease in injection volume for ADVATE reconstituted in&nbsp;2&nbsp;ml
sterilised water for injections, if hypersensitivity reactions occur there is
less time to react by stopping the injection. Therefore, caution is advised
during injection of ADVATE reconstituted in&nbsp;2&nbsp;ml sterilised water for
injections, especially in children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed against
the factor VIII procoagulant activity, which are quantified in Bethesda Units
(BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more
than&nbsp;100&nbsp;exposure days who have a previous history of inhibitor
development. Therefore, it is recommended to monitor all patients carefully for
inhibitor occurrence following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical relevance
of inhibitor development will depend on the titre of the inhibitor, with low
titre inhibitors which are transiently present or remain consistently low titre
posing less of a risk of insufficient clinical response than high titre
inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical
observations and laboratory tests. If the expected factor VIII activity plasma
levels are not attained, or if bleeding is not controlled with an appropriate dose,
testing for factor VIII inhibitor presence should be performed. In patients
with high levels of inhibitor, factor VIII therapy may not be effective and
other therapeutic options should be considered. Management of such patients
should be directed by physicians with experience in the care of haemophilia and
factor VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Misapplication of ADVATE</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For ADVATE
reconstituted with&nbsp;2&nbsp;ml sterilised water for injections,
misapplication (intra&#8209;arterially or paravenously) may lead to mild, short
term injection site reactions, such as bruising and erythema.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central
venous access device (CVAD) is required, risk of CVAD&#8209;related
complications including local infections, bacteremia and catheter site
thrombosis should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Excipient related considerations</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and
batch number of the product are recorded </span><span lang=EN-GB>in order to
maintain a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal reproduction
studies have not been conducted with factor VIII. Based on the rare occurrence
of haemophilia A in women, experience regarding the use of factor VIII during pregnancy
and breast&#8209;feeding is not available. Therefore, factor VIII should be
used during pregnancy and breast-feeding only if clearly indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>ADVATE has no influence on the
ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Summary of
the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE
reporting in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The
ADRs that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills,
flushing, generalised urticaria, headache, hives, hypotension, lethargy,
nausea, restlessness, </span><span lang=EN-GB style='font-size:11.0pt'>tachycardia,
tightness of the chest, tingling, vomiting, wheezing) have been observed rarely
and may in some cases progress to</span><span lang=EN-GB style='font-size:11.0pt'>
severe anaphylaxis (including shock</span><span lang=EN-GB style='font-size:
11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster protein
with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A
treated with factor VIII, including with ADVATE. If such inhibitors occur, the
condition will manifest itself as an insufficient clinical response. In such
cases, it is recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical
trials and from spontaneous reporting. The table is according to the MedDRA
system organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following convention:
very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to
&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare
(&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of
decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.42%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Injury, poisoning and procedural
  complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.42%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

<p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>a) Calculated based on
total number of patients who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred
in one patient during continuous infusion of ADVATE following surgery
(postoperative days&nbsp;10&#8209;14). Haemostasis was maintained at all times
during this period and both plasma factor VIII levels and clearance rates
returned to appropriate levels by postoperative day&nbsp;15. Factor VIII
inhibitor assays performed after completion of continuous infusion and at study
termination were negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>c) ADR explained in the section
below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs =
previously-treated patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically
significant upward trend in titres,&nbsp;4&nbsp;displayed sustained peaks or
transient spikes and one patient had both but no clinical symptoms. Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to murine
IgG,&nbsp;10&nbsp;showed a statistically significant upward trend,&nbsp;2&nbsp;displayed
a sustained peak or transient spike and one patient had both. Four of these
patients reported isolated events of urticaria, pruritus, rash, and slightly
elevated eosinophil counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
reactions include anaphylaxis and have been manifested by dizziness,
paresthesias, rash, flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
ADRs were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>No symptoms of overdose with
recombinant coagulation factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic group:
antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The factor VIII/von Willebrand Factor complex consists of two molecules
(factor VIII and von Willebrand Factor) with different physiological functions.
ADVATE contains recombinant coagulation factor VIII (octocog alfa), a glycoprotein
that is biologically equivalent to the factor VIII glycoprotein found in human
plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient,
octocog alfa binds to endogenous von Willebrand Factor in the patients
circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,
accelerating the conversion of Factor X to activated Factor X. Activated Factor
X converts prothrombin to thrombin. Thrombin then converts fibrinogen into
fibrin and a clot can be formed. Haemophilia A is a sex&#8209;linked hereditary
disorder of blood coagulation due to decreased levels of factor VIII activity
and results in profuse bleeding into joints, muscles or internal organs, either
spontaneously or as a result of accidental or surgical trauma. The plasma
levels of factor VIII are increased by replacement therapy, thereby enabling a
temporary correction of the factor VIII deficiency and correction of the
bleeding tendency.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected. Within
a sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done
for&nbsp;30&nbsp;<span style='letter-spacing:-.15pt'>paediatric</span> subjects
on ITI (in study&nbsp;060703). A non-interventional prospective registry
(PASS-INT-004) documented ITI in 44 paediatric and adult subjects of whom 36
completed ITI therapy. Data show that immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23)
with a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a specific formula)
was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated
patients with severe to moderately severe haemophilia A (baseline factor VIII
&#8804;&nbsp;2%). The analysis of plasma samples was conducted in a central
laboratory using a one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="21%" valign=top style='width:21.26%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="12%" valign=top style='width:12.78%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.0%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="16%" valign=top style='width:16.88%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="19%" valign=top style='width:19.58%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="21%" valign=top style='width:21.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="16%" valign=top style='width:16.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Adjusted Incremental Recovery at Cmax
  (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="12%" valign=top style='width:12.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="16%" valign=top style='width:16.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="16%" valign=top style='width:16.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=FR style='font-size:10.0pt'>Maximum Plasma
  Concentration Post Infusion (IU/dl)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>110.5  30.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="16%" valign=top style='width:16.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>100.5  25.6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>107.6  27.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>111.3  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="16%" valign=top style='width:16.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="16%" valign=top style='width:16.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.26%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="12%" valign=top style='width:12.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="14%" valign=top style='width:14.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="16%" valign=top style='width:16.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.5%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>a</span></sup><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:10.0pt'>Calculated
as (Cmax - baseline Factor VIII) divided by the dose in IU/kg, where Cmax is
the maximal post-infusion Factor VIII measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
haemostatic efficacy of ADVATE in the paediatric population are similar to that
of adult patients. Adjusted recovery and terminal half&#8209;life (t<sub></sub>)
was approximately&nbsp;20% lower in young children (less than&nbsp;6&nbsp;years
of age) than in adults, which may be due in part to the known higher plasma
volume per kilogram body weight in younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Pharmacokinetic data with
ADVATE on previously untreated patients are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A local
tolerance study in rabbits showed that ADVATE reconstituted with&nbsp;2&nbsp;ml
of sterilised water for injections is well tolerated after intravenous
administration. Slight transient reddening at the administration site was
observed after intraarterial application and after paravenous administration.
However, no correlating adverse histopathological changes could be observed
indicating a transient nature of this finding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Sterilised water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months
storage at room temperature should be recorded on the product carton. The
product may not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage conditions
</span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB> of the
medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Both the powder
vial and the vial containing 2&nbsp;ml solvent are of type I glass closed with
chlorobutyl rubber stoppers. The product is provided in one of the following
configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;2&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 2 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be
administered intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Reconstitution with the
BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1. If the product is
still stored in a refrigerator, take both the ADVATE powder and solvent vials
from the refrigerator and let them reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>2. Wash your hands thoroughly
</span><span lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder stopper.
The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image013.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Reconstitution with the </span><span lang=EN-GB>BAXJECT&nbsp;III
system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister (contains
powder and solvent vials preassembled with the system for reconstitution) from
the refrigerator and let it reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the ADVATE
vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass
through the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image003.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image004.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral
medicinal products should be inspected for particulate matter prior to
administration, whenever solution and container permit. Only a clear and
colourless solution should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Attach a butterfly needle to the syringe. Inject
intravenously. The solution should be administered slowly, at a rate as
determined by the patients comfort level, not to exceed&nbsp;10&nbsp;ml per
minute. The pulse rate should be determined before and during administration of
ADVATE. Should a significant increase occur, reducing the rate of administration
or temporarily interrupting the injection usually allows the symptoms to
disappear promptly (see sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/009</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/019</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Date of first authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU powder and solvent for solution
for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each vial
contains nominally&nbsp;1500&nbsp;IU human coagulation factor VIII (rDNA),
octocog alfa. ADVATE contains approximately&nbsp;750&nbsp;IU per ml of human
coagulation factor VIII (rDNA), octocog alfa after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The potency (International Units) is determined using the European
Pharmacopoeia chromogenic assay. The specific activity of ADVATE is approximately&nbsp;4,000&#8209;10,000&nbsp;IU/mg&nbsp;protein.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein
that has 2332 amino acids. It is </span><span lang=EN-GB>produced by
recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human&#8209; or animal&#8209;derived
protein in the cell culture process, purification or final formulation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipients
with known effect</span></u><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 0.45&nbsp;mmol sodium (10&nbsp;mg) per vial.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder: White to
off&#8209;white friable powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solvent: Clear
and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4. Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment and
prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII
deficiency). ADVATE is indicated in all age groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2 Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment should
be initiated under the supervision of a physician experienced in the treatment of
haemophilia and with resuscitation support immediately available in case of
anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
duration of the substitution therapy depend on the severity of the factor VIII
deficiency, on the location and extent of the bleeding and on the patients
clinical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The number of
units of factor VIII is expressed in International Units (IU), which are
related to the WHO standard for factor VIII products. Factor VIII activity in
plasma is expressed either as a percentage (relative to normal human plasma) or
in IUs (relative to the international standard for factor VIII in plasma).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One </span><span
lang=EN-GB>International Unit (</span><span lang=EN-GB>IU) of factor VIII
activity is equivalent to that quantity of factor VIII in one ml of normal
human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The calculation
of the required dose of factor VIII is based on the empirical finding
that&nbsp;1&nbsp;IU factor VIII per kg body weight raises the plasma factor
VIII activity by&nbsp;2&nbsp;IU/dl. The required dose is determined using the
following formula:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Required units (IU)&nbsp;=&nbsp;body weight (kg) x
desired factor VIII rise (%) x&nbsp;0.5</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table&nbsp;1&nbsp;can be
used to guide dosing in bleeding episodes and surgery:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Table&nbsp;1&nbsp;</span></b><span lang=EN-GB>Guide for dosing in
  bleeding episodes and surgery</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
  haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="26%" valign=top style='width:26.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
  level required (% or IU/dl)</span></b></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
  of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life
  threatening haemorrhages.</span></p>
  </td>
  <td width="26%" valign=top style='width:26.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours
  (8&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6)
  for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more until pain and acute disability
  are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;12&nbsp;hours for patients under the age of&nbsp;6) until
  threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="33%" valign=top style='width:33.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="26%" valign=top style='width:26.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at
  least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) until adequate wound healing, then continue
  therapy for at least another&nbsp;7&nbsp;days to maintain a factor VIII
  activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the
individual case. Under certain circumstances (e.g. presence of a low&#8209;titre
inhibitor), doses larger than those calculated using the formula may be
necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
course of treatment, appropriate determination of plasma factor VIII levels is advised
to guide the dose to be administered and the frequency of repeated injections.
In the case of major surgical interventions in particular, precise monitoring
of the substitution therapy by means of plasma factor VIII activity assay is
indispensable. Individual patients may vary in their response to factor VIII,
achieving different levels of <i>in vivo</i> recovery and demonstrating
different half&#8209;lives.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Prophylaxis</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For long&#8209;term
prophylaxis against bleeding in patients with severe haemophilia A, the usual doses
are&nbsp;20&nbsp;to&nbsp;40&nbsp;IU of factor VIII per kg body weight at
intervals of&nbsp;2&nbsp;to&nbsp;3&nbsp;days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For on demand
treatment dosing in paediatric patients (0 to 18 years of age) does not differ
from adult patients. In patients under the age of 6, doses of 20 to 50&nbsp;IU
of factor VIII per kg body weight 3 to 4 times weekly are recommended for
prophylactic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE should be administered via the intravenous route. In case of
administration by a non health care professional appropriate training is
needed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The rate of
administration should be determined to ensure the comfort of the patient up to
a maximum of&nbsp;10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, the solution is clear, colourless, free from foreign particles
and has a pH of&nbsp;6.7&nbsp;to&nbsp;7.3.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions on reconstitution </span><span lang=EN-GB>of the medicinal
product before </span><span lang=EN-GB>administration, see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Hypersensitivity to the active substance or to any of
the excipients </span><span lang=EN-GB>listed in section 6.1 </span><span
lang=EN-GB>or to mouse or hamster proteins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4 Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
hypersensitivity reactions, including anaphylaxis, have been reported with
ADVATE. The product contains traces of mouse and hamster proteins. If symptoms
of hypersensitivity occur, patients should be advised to discontinue use of the
product immediately and contact their physician. Patients should be informed of
the early signs of hypersensitivity reactions including hives, generalised urticaria,
tightness of the chest, wheezing, hypotension and anaphylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of
shock, standard medical treatment for shock should be implemented.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
decrease in injection volume for ADVATE reconstituted in&nbsp;2&nbsp;ml
sterilised water for injections, if hypersensitivity reactions occur there is
less time to react by stopping the injection. Therefore, caution is advised during
injection of ADVATE reconstituted in&nbsp;2&nbsp;ml sterilised water for
injections, especially in children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Inhibitors</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
neutralising antibodies (inhibitors) to factor VIII is a known complication in
the management of individuals with haemophilia A. These inhibitors are usually
IgG </span><span lang=EN-GB>immunoglobulins </span><span lang=EN-GB>directed
against the factor VIII procoagulant activity, which are quantified in Bethesda
Units (BU) per ml of plasma using the modified assay. The risk of developing
inhibitors is correlated to the severity of the disease as well as the exposure
to factor VIII, this risk being highest within the first&nbsp;20&nbsp;exposure
days. Rarely, inhibitors may develop after the first&nbsp;100&nbsp;exposure
days.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
recurrent inhibitor (low titre) have been observed after switching from one
factor VIII product to another in previously treated patients with more
than&nbsp;100&nbsp;exposure days who have a previous history of inhibitor
development. Therefore, it is recommended to monitor all patients carefully for
inhibitor occurrence following any product switch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
relevance of inhibitor development will depend on the titre of the inhibitor,
with low titre inhibitors which are transiently present or remain consistently
low titre posing less of a risk of insufficient clinical response than high
titre inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In general, all
patients treated with coagulation factor VIII products should be carefully
monitored for the development of inhibitors by appropriate clinical
observations and laboratory tests. If the expected factor VIII activity plasma
levels are not attained, or if bleeding is not controlled with an appropriate
dose, testing for factor VIII inhibitor presence should be performed. In patients
with high levels of inhibitor, factor VIII therapy may not be effective and other
therapeutic options should be considered. Management of such patients should be
directed by physicians with experience in the care of haemophilia and factor
VIII inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Misapplication of ADVATE</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For ADVATE
reconstituted with&nbsp;2&nbsp;ml sterilised water for injections,
misapplication (intra&#8209;arterially or paravenously) may lead to mild, short
term injection site reactions, such as bruising and erythema.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Catheter&#8209;related complications in treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If central
venous access device (CVAD) is required, risk of CVAD&#8209;related
complications including local infections, bacteremia and catheter site
thrombosis should be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Excipient
related considerations</span></u></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Sodium</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains 10 mg
sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily
intake of 2 g sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered to a patient, the name and
batch number of the product are recorded </span><span lang=EN-GB>in order to
maintain a link between the patient and the batch of the medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Paediatric
population</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5 Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed with ADVATE.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal
reproduction studies have not been conducted with factor VIII. Based on the
rare occurrence of haemophilia A in women, experience regarding the use of
factor VIII during pregnancy and breast&#8209;feeding is not available. Therefore,
factor VIII should be used during pregnancy and breast-feeding only if clearly
indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>ADVATE has no influence on the ability to drive and
use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Summary of
the safety profile</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
with ADVATE included 418 subjects with at least one exposure to ADVATE reporting
in total 93 adverse drug reactions (ADRs). </span><span lang=EN-GB>The ADRs
that occurred in the highest frequency were development of neutralising
antibodies to factor VIII (inhibitors), headache and fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Hypersensitivity or allergic reactions (which may
include angioedema, burning and stinging at the infusion site, chills, flushing,
generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness,
</span><span lang=EN-GB style='font-size:11.0pt'>tachycardia, tightness of the
chest, tingling, vomiting, wheezing) have been observed rarely and may in some
cases progress to</span><span lang=EN-GB style='font-size:11.0pt'> severe
anaphylaxis (including shock</span><span lang=EN-GB style='font-size:11.0pt'>).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>Development of antibodies to mouse and/or hamster
protein with related hypersensitivity reactions may be observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Development of
neutralising antibodies (inhibitors) may occur in patients with haemophilia A
treated with factor VIII, including with ADVATE. If such inhibitors occur, the
condition will manifest itself as an insufficient clinical response. In such
cases, it is recommended that a specialised haemophilia centre be contacted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Tabulated summary of adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table&nbsp;2&nbsp;provides the frequency of adverse drug reactions in clinical
trials and from spontaneous reporting. The table is according to the MedDRA
system organ classification (SOC and Preferred Term Level).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Frequency categories are defined according to the following convention:
very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100&nbsp;to &lt;&nbsp;1/10),
uncommon (&#8805;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare
(&#8805;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000), very rare
(&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of
decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 4.0pt 0in 4.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Table&nbsp;2&nbsp;</span></b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency of adverse drug reactions
   (ADRs) in clinical trials and from spontaneous reports</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width="44%" valign=top style='width:44.24%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 4.0pt 0in 4.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=SV style='font-size:10.0pt'>MedDRA Standard System Organ Class</span></b></p>
   </td>
   <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 4.0pt 0in 4.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Adverse reaction</span></b></p>
   </td>
   <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 4.0pt 0in 4.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Frequency<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Infections and infestations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Influenza</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laryngitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="44%" rowspan=2 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Blood and lymphatic system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Factor VIII inhibition</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon (PTPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Very common (PUPs)<sup>d</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Lymphangitis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=2 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Immune system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Anaphylactic reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hypersensitivity<sup>c</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=7 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nervous system disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Headache</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dizziness</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Memory impairment</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Syncope</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tremor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Migraine</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dysgeusia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Eye inflammation</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Cardiac disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Palpitations</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vascular disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hot flush</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pallor</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dyspnoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Gastrointestinal disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Diarrhoea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Abdominal pain upper</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Nausea</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vomiting</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pruritus</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rash</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Hyperhidrosis</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Urticaria</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=10 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>General disorders and administration site conditions</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Pyrexia</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Peripheral oedema</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest pain</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chest discomfort</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Chills</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Feeling abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vessel puncture site haematoma</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Fatigue</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Injection site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt;height:6.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Malaise</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Not known</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=4 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Investigations</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Monocyte Count increased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Coagulation factor VIII level decreased<sup>b</sup></span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Haematocrit decreased</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Laboratory test abnormal</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="44%" rowspan=3 valign=top style='width:44.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Injury, poisoning and procedural
  complications</span></p>
  </td>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Post procedural complication</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Post procedural haemorrhage</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Procedural site reaction</span></p>
  </td>
  <td width="23%" valign=top style='width:23.22%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.0pt 0in 4.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Uncommon</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoHeader style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>a) Calculated based on
total number of patients who received ADVATE (418).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>b)</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>The unexpected decrease in coagulation factor VIII levels occurred
in one patient during continuous infusion of ADVATE following surgery (postoperative
days&nbsp;10&#8209;14). Haemostasis was maintained at all times during this
period and both plasma factor VIII levels and clearance rates returned to
appropriate levels by postoperative day&nbsp;15. Factor VIII inhibitor assays
performed after completion of continuous infusion and at study termination were
negative.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>c) ADR explained in the
section below.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>d) Frequency is based on studies with all FVIII
products which included patients with severe haemophilia A. PTPs =
previously-treated patients, PUPs = previously-untreated patients</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>ADRs specific to residues from the manufacturing process</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to Chinese
hamster ovary (CHO) cell protein,&nbsp;3&nbsp;showed a statistically significant
upward trend in titres,&nbsp;4&nbsp;displayed sustained peaks or transient
spikes and one patient had both but no clinical symptoms. Of
the&nbsp;229&nbsp;treated patients who were assessed for antibodies to murine
IgG,&nbsp;10&nbsp;showed a statistically significant upward trend,&nbsp;2&nbsp;displayed
a sustained peak or transient spike and one patient had both. Four of these
patients reported isolated events of urticaria, pruritus, rash, and slightly
elevated eosinophil counts amongst repeated exposures to the study product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Hypersensitivity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Allergic type
reactions include anaphylaxis and have been manifested by dizziness,
paresthesias, rash, flushing, face swelling, urticaria, and pruritus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
ADRs were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse
reactions via the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>No symptoms of overdose with recombinant coagulation
factor&nbsp;VIII have been reported.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Pharmacotherapeutic group: antihaemorrhagics, blood
coagulation factor VIII. ATC code: B02BD02.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The factor VIII/von Willebrand Factor complex consists of two
molecules (factor VIII and von Willebrand Factor) with different physiological
functions. ADVATE contains recombinant coagulation factor VIII (octocog alfa),
a glycoprotein that is biologically equivalent to the factor VIII glycoprotein
found in human plasma.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Octocog alfa is
a glycoprotein consisting of&nbsp;2332&nbsp;amino acids with an approximate
molecular mass of&nbsp;280&nbsp;kD. When infused into a haemophilia patient,
octocog alfa binds to endogenous von Willebrand Factor in the patients
circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,
accelerating the conversion of Factor X to activated Factor X. Activated Factor
X converts prothrombin to thrombin. Thrombin then converts fibrinogen into
fibrin and a clot can be formed. Haemophilia A is a sex&#8209;linked hereditary
disorder of blood coagulation due to decreased levels of factor VIII activity
and results in profuse bleeding into joints, muscles or internal organs, either
spontaneously or as a result of accidental or surgical trauma. The plasma
levels of factor VIII are increased by replacement therapy, thereby enabling a
temporary correction of the factor VIII deficiency and correction of the
bleeding tendency.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data on Immune
Tolerance Induction (ITI) in patients with inhibitors have been collected.
Within a sub&#8209;study of PUP&#8209;study&nbsp;060103, ITI&#8209;treatments
in&nbsp;11&nbsp;PUPs were documented. Retrospective chart review was done
for&nbsp;30&nbsp;<span style='letter-spacing:-.15pt'>paediatric</span> subjects
on ITI (in study&nbsp;060703). A non-interventional prospective registry (PASS-INT-004)
documented ITI in 44 paediatric and adult subjects of whom 36 completed ITI
therapy. Data show that immune tolerance may be achieved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study 060201
two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an
individualized pharmacokinetic guided dosing regimen (within a range of 20 to
80 IU of factor VIII per kg body weight at intervals of 72  6 hours, n=23) with
a standard prophylactic dosing regimen (20 to 40 IU/kg every 48 6 hours,
n=30). The pharmacokinetic guided dosing regimen (according to a specific
formula) was targeted to maintain factor VIII trough levels &#8805; 1% at the
inter-dosing interval of 72 hours. </span><span lang=EN-GB>The data from this
study demonstrate that the two prophylactic dosing regimens are comparable in
terms of reduction of bleeding rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has waived the obligation to submit the results of studies
with ADVATE in all subsets of the paediatric population in haemophilia A
(congenital factor VIII deficiency) in &quot;Immune Tolerance Induction (ITI)
in patients with haemophilia A (congenital factor VIII deficiency) who have
developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis
of bleeding in patients with haemophilia A (congenital factor VIII
deficiency)&quot;. (see section 4.2 for information on paediatric use).</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All
pharmacokinetic studies with ADVATE were conducted in previously treated patients
with severe to moderately severe haemophilia A (baseline factor VIII
&#8804;&nbsp;2%). The analysis of plasma samples was conducted in a central
laboratory using a one&#8209;stage clotting assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>A total of 195 subjects with severe haemophilia A (baseline factor
VIII &lt;&nbsp;1%) provided PK parameters that were included in the
Per-Protocol PK analysis set. Categories of these analyses for infants (1 month
to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5
to &lt;12 years of age), adolescents (12 to &lt;18 years of age), and adults
(18 years of age and older) were used to summarize PK parameters, where age was
defined as age at time of PK infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>Table&nbsp;3</span></b><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;Summary of Pharmacokinetic Parameters of
   ADVATE per Age Group with severe haemophilia A (baseline factor VIII
   &lt;&nbsp;1%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Parameter
   (mean  standard deviation)</span></p>
   </td>
   <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Infants</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=5)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Children</span></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n=30)</span></b></p>
   </td>
   <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Older
   Children</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=18)</span></p>
   </td>
   <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adolescents</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=33)</span></p>
   </td>
   <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>Adults</span></p>
   <p class=MsoCaption style='line-height:normal'><span lang=EN-GB>(n=109)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText align=left style='margin:0in;text-align:left'><span
  lang=PT>Total AUC (IU*h/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1362.1  311.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1180.0  432.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1506.6  530.0</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1317.1  438.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TableText style='margin:0in'><span lang=EN-GB>1538.5  519.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Adjusted Incremental Recovery at Cmax
  (IU/dL per IU/kg)<sup>a</sup></span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>1.8  0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.0  0.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.1  0.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>2.2  0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Half-life (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.0  1.5</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>9.6  1.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.8  3.8</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.1  3.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.9  4.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR style='font-size:10.0pt'>Maximum Plasma Concentration Post Infusion
  (IU/dl)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>110.5 
  30.2</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>90.8  19.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>100.5 
  25.6</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>107.6 
  27.6</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>111.3 
  27.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Mean Residence Time (h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>11.0  2.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>12.0  2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.1  4.7</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>15.0  5.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>16.2  6.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Volume of Distribution at Steady State
  (dl/kg)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.4  0.1</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.6  0.2</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>0.5  0.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="20%" valign=top style='width:20.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Clearance (ml/kg*h)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.06%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.9  0.9</span></p>
  </td>
  <td width="14%" valign=top style='width:14.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.8  1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.8  1.5</span></p>
  </td>
  <td width="15%" valign=top style='width:15.82%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>4.1  1.0</span></p>
  </td>
  <td width="19%" valign=top style='width:19.12%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-size:10.0pt'>3.6  1.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> </span><span lang=EN-GB
style='font-size:10.0pt'>Calculated as (Cmax - baseline Factor VIII) divided by
the dose in IU/kg, where Cmax is the maximal post-infusion Factor VIII
measurement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
haemostatic efficacy of ADVATE in the paediatric population are similar to that
of adult patients. Adjusted recovery and terminal half&#8209;life (t<sub></sub>)
was approximately&nbsp;20% lower in young children (less than&nbsp;6&nbsp;years
of age) than in adults, which may be due in part to the known higher plasma
volume per kilogram body weight in younger patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Pharmacokinetic data with ADVATE on previously
untreated patients are currently not available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3 Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
data reveal no special hazard for humans based on studies of safety
pharmacology, acute toxicology, repeated dose toxicity, local toxicity and
genotoxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A local
tolerance study in rabbits showed that ADVATE reconstituted with&nbsp;2&nbsp;ml
of sterilised water for injections is well tolerated after intravenous
administration. Slight transient reddening at the administration site was observed
after intraarterial application and after paravenous administration. However,
no correlating adverse histopathological changes could be observed indicating a
transient nature of this finding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6. PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Powder</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Histidine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trehalose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Calcium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trometamol</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glutathione
(reduced)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Solvent</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Sterilised water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After
reconstitution, from a microbiological point of view, the product should be
used immediately. However, chemical and physical in&#8209;use stability has
been demonstrated for&nbsp;3&nbsp;hours at&nbsp;25&nbsp;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the shelf
life, the product may be kept at room temperature (up to&nbsp;25&nbsp;C) for a
single period not exceeding&nbsp;6&nbsp;months. The end of the 6&nbsp;months storage
at room temperature should be recorded on the product carton. The product may
not be returned to refrigerated storage again.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE with
BAXJECT II device: Keep the product vial in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE in
BAXJECT III system: Keep the sealed blister in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions </span><span lang=EN-GB>after reconstitution</span><span lang=EN-GB>
of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5 Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Both the powder
vial and the vial containing 2&nbsp;ml solvent are of type I glass closed with
chlorobutyl rubber stoppers. The product is provided in one of the following
configurations:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE with BAXJECT II device: Each pack
contains a powder vial, a vial containing&nbsp;2&nbsp;ml solvent and a device
for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ADVATE in BAXJECT III system: Each pack contains
a ready to use BAXJECT&nbsp;III system in a sealed blister (the powder vial and
the vial containing 2 ml solvent are preassembled with the system for
reconstitution).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is to be
administered intravenously after reconstitution of the product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
reconstituted solution should be inspected visually for any foreign particulate
matter and/or discoloration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After reconstitution
the solution should be clear, colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
solutions that are cloudy or have deposits.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For administration the use of a luer&#8209;lock
syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use within three hours after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the preparation after
reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Any unused medicinal product or waste material
should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Reconstitution with the BAXJECT II device</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For reconstitution use only the sterilised water
for injections and the reconstitution device provided in the pack.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Aseptic Technique should be used</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1. If the product is
still stored in a refrigerator, take both the ADVATE powder and solvent vials
from the refrigerator and let them reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>2. Wash your hands
thoroughly </span><span lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. Open the package of <span style='text-transform:
uppercase'>BaxJect&nbsp;II</span> device by peeling away the paper lid without
touching the inside (Fig. a). Do not remove the device from the package. Do not
use if the BAXJECT II device, its sterile barrier system or its packaging is
damaged or shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Turn the package over and insert the clear
plastic spike through the solvent stopper. Grip the package at its edge and
pull the package off <span style='text-transform:uppercase'>BaxJect&nbsp;II </span>(Fig.
b). Do not remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>7. For reconstitution only the sterilised water
for injections and the reconstitution device provided in the pack should be
used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder
stopper. The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a   Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image013.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Reconstitution with the </span><span lang=EN-GB>BAXJECT&nbsp;III
system</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for
reconstitution) from the refrigerator and let it reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass through
the device filter. The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute).
After reconstitution the solution should be clear, colourless and free from
foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span class=a><b><span lang=PT
  style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image003.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal;page-break-after:
  avoid'><span lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image004.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><u><span lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use Aseptic
Technique</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Parenteral
medicinal products should be inspected for particulate matter prior to
administration, whenever solution and container permit. Only a clear and colourless
solution should be used.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II /
BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the syringe
to BAXJECT&nbsp;II / BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the reconstituted
solution has to be on top). Draw the reconstituted solution into the syringe by
pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Attach a butterfly needle to the syringe.
Inject intravenously. The solution should be administered slowly, at a rate as
determined by the patients comfort level, not to exceed&nbsp;10&nbsp;ml per
minute. The pulse rate should be determined before and during administration of
ADVATE. Should a significant increase occur, reducing the rate of
administration or temporarily interrupting the injection usually allows the
symptoms to disappear promptly (see sections&nbsp;4.4&nbsp;and&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7. MARKETING AUTHORISATION
HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/010</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/020</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Date of first authorisation:&nbsp;02&nbsp;March&nbsp;2004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal:&nbsp;20&nbsp;December&nbsp;2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10. DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this </span><span lang=EN-GB>medicinal </span><span lang=EN-GB>product
is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu/"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a>.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>A. MANUFACTURERS OF THE
BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>B. CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>C. OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>D. CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'>A MANUFACTURERS
OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH
RELEASE</h1>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturers of the biological active substance</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Baxalta Manufacturing
Srl</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Route de Pierre&#8209;&#8209;Bot&nbsp;111</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CH&#8209;2000&nbsp;Neuchtel</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Switzerland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Baxalta
Manufacturing SARL<br>
Singapore Branch<br>
2A Woodlands Industrial Park D Street 2<br>
Singapore 737779<br>
Singapore</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Baxalta Belgium Manufacturing SA</p>

<p class=MsoNormal style='line-height:normal'>Boulevard Ren Branquart&nbsp;80</p>

<p class=MsoNormal style='line-height:normal'>B&#8209;7860&nbsp;Lessines</p>

<p class=MsoNormal style='line-height:normal'>Belgium</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'>B CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Medicinal product subject to restricted medical prescription (see Annex
I: Summary of Product Characteristics, section&nbsp;4.2)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'>C OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</h1>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The marketing authorisation holder shall submit </span><span
lang=EN-GB>periodic safety update reports</span><span lang=EN-GB> for this
product in accordance with the requirements set out in the list of Union
reference dates (EURD list) </span><span lang=EN-GB>provided for under Article
107c(7) of Directive 2001/83</span><span lang=EN-GB>/EC</span><span lang=EN-GB>
and </span><span lang=EN-GB>published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 align=left style='margin-left:28.35pt;text-align:left;text-indent:-28.35pt'>D. CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</h1>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The MAH shall perform the required pharmacovigilance activities and
interventions detailed in the agreed RMP presented in Module 1.8.2 of the
Marketing Authorisation and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>An updated RMP
should be submitted</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol;
layout-grid-mode:line'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>If the dates for submission of a PSUR and the update of a RMP coincide,
they can be submitted at the same time.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:-.05pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:center;
text-indent:-28.35pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1>A. LABELLING</h1>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;II Device)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa (recombinant
human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;250&nbsp;IU
octocog alfa, approx.&nbsp;50&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;250&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml sterilised
water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>250&nbsp;IU
octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;250&nbsp;IU
octocog alfa, approx.&nbsp;50&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;250&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of 6&nbsp;month
period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/011</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if
packaging is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
5&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>ADVATE&nbsp;250</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image014.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image015.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image016.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><span style='position:relative;
z-index:-1895825920'><span style='position:absolute;left:0px;top:-76738px;
width:88px;height:1px'><img width=88 height=1
src="Advate-h-520-e_files/image017.jpg"></span></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;500&nbsp;IU
octocog alfa, approx.&nbsp;100&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific activity:
approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and solvent
for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;500&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml
sterilised water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of 6&nbsp;month
period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>500&nbsp;IU
octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;500&nbsp;IU
octocog alfa, approx.&nbsp;100&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;500&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of 6&nbsp;month
period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately or
within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED
FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/012</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if packaging
is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
5&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image014.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image015.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image018.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;1000&nbsp;IU
octocog alfa, approx.&nbsp;200&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: mannitol,
sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and solvent
for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;1000&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml
sterilised water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1000&nbsp;IU
octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa (recombinant
human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;1000&nbsp;IU
octocog alfa, approx.&nbsp;200&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;1000&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml sterilised
water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. </span></b><b><span
lang=EN-GB>NAME</span><span lang=EN-GB> OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if
packaging is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
5&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image019.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image020.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image018.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;1500&nbsp;IU
octocog alfa, approx.&nbsp;300&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;1500&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml sterilised
water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED
FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1500&nbsp;IU octocog
alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;1500&nbsp;IU
octocog alfa, approx.&nbsp;300&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;1500&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep</span><span
lang=EN-GB> out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED
FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/014</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. </span></b><b><span
lang=EN-GB>NAME</span><span lang=EN-GB> OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if
packaging is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
5&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image021.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image022.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image023.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;2000&nbsp;IU
octocog alfa, approx.&nbsp;400&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific activity:
approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and solvent
for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;2000&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml
sterilised water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of 6&nbsp;month
period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the original
package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED
FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/005</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2000&nbsp;IU
octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;2000&nbsp;IU
octocog alfa, approx.&nbsp;400&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific activity:
approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;2000&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/015</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if packaging
is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
5&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image024.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image025.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image023.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;2000</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;3000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;3000&nbsp;IU
octocog alfa, approx.&nbsp;600&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: mannitol,
sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;3000&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml sterilised
water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/006</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;</span><span
lang=EN-GB>3000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;3000&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3000&nbsp;IU octocog
alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;3000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;3000&nbsp;IU
octocog alfa, approx.&nbsp;600&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;3000&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;5&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/016</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;3000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;3000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if
packaging is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
5&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;3000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image021.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image022.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image023.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;3000</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;250&nbsp;IU
octocog alfa, approx.&nbsp;125&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;250&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;2&nbsp;ml
sterilised water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/007</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>250&nbsp;IU octocog
alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;250&nbsp;IU
octocog alfa, approx.&nbsp;125&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific activity:
approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and solvent
for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;250&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;2&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Intravenous use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>End of 6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Do not use after the expiry date.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Use immediately or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>EU/1/03/271/017</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Lot</span><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='background:silver'>Medicinal product subject to
medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>ADVATE&nbsp;250</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
background:silver'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU powder and solvent for
solution for injection</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. </span><span
lang=EN-GB>EXPIRY</span></b><b><span lang=EN-GB> DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. </span><span
lang=EN-GB>BATCH</span></b><b><span lang=EN-GB> NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. </span><span
lang=EN-GB>OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if
packaging is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
2&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. </span><span
lang=EN-GB>NAME</span></b><b><span lang=EN-GB> OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. </span><span
lang=EN-GB>EXPIRY</span></b><b><span lang=EN-GB> DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. </span><span
lang=EN-GB>OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image021.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image022.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image023.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;250</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;500&nbsp;IU
octocog alfa, approx.&nbsp;250&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific activity:
approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;500&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;2&nbsp;ml
sterilised water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of 6&nbsp;month
period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/008</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>500&nbsp;IU
octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;500&nbsp;IU
octocog alfa, approx.&nbsp;250&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;500&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;2&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the original
package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/018</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if
packaging is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
2&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. </span><span
lang=EN-GB>NAME</span></b><b><span lang=EN-GB> OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. </span><span
lang=EN-GB>NAME</span></b><b><span lang=EN-GB> OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. </span><span
lang=EN-GB>EXPIRY</span></b><b><span lang=EN-GB> DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. </span><span
lang=EN-GB>BATCH</span></b><b><span lang=EN-GB> NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. </span><span
lang=EN-GB>OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image024.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image025.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image023.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;500</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa (recombinant
human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;1000&nbsp;IU
octocog alfa, approx.&nbsp;500&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific activity:
approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: mannitol,
sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and solvent
for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;1000&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;2&nbsp;ml sterilised
water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of 6&nbsp;month
period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/009</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1000&nbsp;IU
octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;1000&nbsp;IU
octocog alfa, approx.&nbsp;500&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
mannitol, sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;1000&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;2&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of 6&nbsp;month
period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the original
package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/019</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if
packaging is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
2&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. </span><span
lang=EN-GB>NAME</span></b><b><span lang=EN-GB> OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. </span><span
lang=EN-GB>BATCH</span></b><b><span lang=EN-GB> NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image024.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image022.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image026.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1000</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;1500&nbsp;IU
octocog alfa, approx.&nbsp;750&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: mannitol,
sodium chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and
solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;1500&nbsp;IU octocog alfa,&nbsp;1&nbsp;vial with&nbsp;2&nbsp;ml
sterilised water for injections,&nbsp;1&nbsp;BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of
6&nbsp;month period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED
FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda Manufacturing
Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/010</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IV use</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1500&nbsp;IU octocog
alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT II DEVICE)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;ml</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>OUTER CARTON (<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa
(recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1&nbsp;vial:&nbsp;1500&nbsp;IU
octocog alfa, approx.&nbsp;750&nbsp;IU/ml after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Specific
activity: approx.&nbsp;4,000&nbsp;&nbsp;10,000&nbsp;IU/mg protein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: mannitol,
sodium chloride, histidine, trehalose, calcium chloride, trometamol,
polysorbate&nbsp;80, glutathione (reduced).</span></p>

<p class=MsoNormal><span lang=EN-GB>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder and solvent
for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contents:&nbsp;1&nbsp;vial
with&nbsp;1500&nbsp;IU octocog alfa and&nbsp;1&nbsp;vial with&nbsp;2&nbsp;ml
sterilised water for injections&nbsp;preassembled in BAXJECT&nbsp;III system.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use,
after reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Single use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE </span></b><b><span
lang=EN-GB>SIGHT AND </span><span lang=EN-GB>REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>End of 6&nbsp;month
period, if stored at room temperature:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use after
the expiry date.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Can be stored at
room temperature (up to&nbsp;25&nbsp;C) for a single period up
to&nbsp;6&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Austria</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/271/020</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>Medicinal product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16. INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>NN:</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder and solvent for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>octocog alfa</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. </span><span
lang=EN-GB>EXPIRY</span></b><b><span lang=EN-GB> DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. </span><span
lang=EN-GB>BATCH</span></b><b><span lang=EN-GB> NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Intravenous
use, after reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Use immediately
or within 3 hours of reconstitution.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Do not use if
packaging is opened or damaged.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Powder vial and
2&nbsp;ml solvent preassembled in BAXJECT III system.</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-before:always;
border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>ASSEMBLY LABEL </span><span lang=EN-GB>(<span style='text-transform:
uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. </span><span
lang=EN-GB>NAME</span></b><b><span lang=EN-GB> OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. </span><span
lang=EN-GB>NAME</span></b><b><span lang=EN-GB> OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Takeda
Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. </span><span
lang=EN-GB>EXPIRY</span></b><b><span lang=EN-GB> DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. </span><span
lang=EN-GB>BATCH</span></b><b><span lang=EN-GB> NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. </span><span
lang=EN-GB>OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image024.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image022.jpg"><img
border=0 width=170 height=136 src="Advate-h-520-e_files/image026.jpg"></span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE POWDER (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE&nbsp;1500</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>VIAL LABEL FOR THE SOLVENT (<span
style='text-transform:uppercase'>BAXJECT&nbsp;III system)</span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sterilised water
for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2. METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4. BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span><span
lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<h1>B. PACKAGE LEAFLET</h1>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;250&nbsp;IU powder and solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;500&nbsp;IU powder and solvent for solution for
injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU powder and solvent for solution for
injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU powder and solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;2000&nbsp;IU powder and solvent for solution for
injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;3000&nbsp;IU powder and solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>octocog alfa (recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor.
This includes any possible side effects not listed in this leaflet. See section
4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What is in
this leaflet</span></b><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. What ADVATE is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. What you need to know before you use ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. How to use ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. How to store ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. W</span></b><b><span
lang=EN-GB>hat ADVATE is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE contains the active substance octocog alfa, human coagulation
factor VIII produced by recombinant DNA technology. Factor VIII is necessary
for the blood to form clots and stop bleedings. In patients with haemophilia A
(inborn lack of factor VIII), it is missing or not working properly.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is used </span><span lang=EN-GB>for the treatment and prevention
of bleeding in patients of all age groups with haemophilia A (an inherited
bleeding disorder caused by lack of factor VIII).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is prepared without the addition of any human&#8209; or
animal&#8209;derived protein in the entire manufacturing process.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2. What you need to know before you use ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use
ADVATE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to octocog alfa or any of
the other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to mouse or hamster proteins</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
unsure about this, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor before using ADVATE. </span><span lang=EN-GB>You should tell your doctor
if you have been previously treated with Factor VIII products, especially if
you developed inhibitors, since there might be a higher risk that it happens again.
Inhibitors are blocking antibodies against factor VIII that reduce the efficacy
of ADVATE to prevent or control bleeding. Development of inhibitors is a known
complication in the treatment of haemophilia A</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'>.</span></span><span
lang=EN-GB> If your bleeding is not controlled with ADVATE, tell your doctor
immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is a rare risk that you may experience an anaphylactic reaction
(a severe, sudden allergic reaction) to ADVATE. You should be aware of the
early signs of allergic reactions such as rash, hives, wheals, generalised itching,
swelling of lips and tongue, difficulty in breathing, wheezing, tightness in the
chest, general feeling of being unwell, and dizziness. These symptoms can
constitute an early symptom of an anaphylactic shock, manifestations of which
may additionally include extreme dizziness, loss of consciousness, and extreme
difficulty in breathing.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If any of these symptoms occur, stop the injection immediately and
contact your doctor. Severe symptoms, including difficulty in breathing and
(near) fainting, require prompt emergency treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Patients developing
Factor VIII inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
inhibitors (antibodies) is a known complication that can occur during treatment
with all Factor VIII medicines. These inhibitors, especially at high levels, stop
the treatment working properly and you or your child will be monitored
carefully for the development of these inhibitors. If you or your childs bleeding
is not being controlled with ADVATE, tell your doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Children and
adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed warnings
and precautions apply to both adults and children (from 0 to 18 years of age).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other medicines
and ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tell your doctor if you are using, have recently used or might use
any other medicines.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pregnancy and
breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant or breast-feeding, think you may be pregnant or are planning to have a
baby, </span><span lang=EN-GB>ask your doctor </span><span lang=EN-GB>for advice
before using this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Driving and using
machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE has no influence
on your ability to drive or to use machines.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ADVATE
contains sodium</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>This medicine
contains 10 mg sodium (main component of cooking salt) per vial. <span
lang=EN-GB>This is equivalent to 0.5 % of the recommended maximum daily dietary
intake of sodium for an adult. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. How to use ADVATE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Treatment with ADVATE will be started by a doctor who is experienced
in the care of patients with haemophilia A.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will calculate your dose of ADVATE (in international
units or IU) depending on your condition and body weight, and on whether it is
used for prevention or treatment of bleeding. The frequency of administration
will depend on how well ADVATE is working for you. Usually, the replacement
therapy with ADVATE is a life&#8209;long treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always use </span><span lang=EN-GB>this medicine</span><span
lang=EN-GB> exactly as your doctor has told you. Check with your doctor if you
are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Prevention of
bleeding</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The usual dose of octocog alfa is&nbsp;20&nbsp;to&nbsp;40&nbsp;IU
per kg body weight, administered every&nbsp;2&nbsp;to&nbsp;3&nbsp;days.
However, in some cases, especially in younger patients, more frequent injections
or higher doses may be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Treatment of bleeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The dose of octocog alfa is calculated depending on your body weight
and the factor VIII levels to be achieved. The target factor VIII levels will
depend on the severity and location of the bleeding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose (IU)&nbsp;=&nbsp;body
weight (kg) x desired Factor VIII rise (% of normal) x&nbsp;0.5</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have the impression that the effect of ADVATE is
insufficient, talk to your doctor.</span></p>

<p class=MsoBodyText3 align=left style='text-align:left;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-weight:normal;font-style:
normal'>Your doctor will perform appropriate laboratory tests to make sure that
you have adequate Factor VIII levels. This is particularly important if you are
having major surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Use in
children and adolescents</span></b><span lang=EN-GB> (from 0 to 18 years of
age)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For the treatment of bleeding the dosing in children does not differ
from adult patients. For the prevention of bleeding in children under the age
of 6, doses of 20 to 50&nbsp;IU per kg body weight 3 to 4&nbsp;times weekly are
recommended. The administration of ADVATE in children (intravenously) does not
differ from the administration in adults. A central venous access device (CVAD)
may become necessary to allow frequent infusions of factor VIII products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>How ADVATE is
given</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is usually injected into a vein (intravenously) by your doctor
or nurse. You or someone else might also administer ADVATE as an injection, but
only after receiving adequate training. Detailed instructions for self&#8209;administration
are given at the end of this package leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you use more
ADVATE than you should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take ADVATE exactly as your doctor has told you. You should
check with your doctor if you are not sure. </span><span lang=EN-GB>If you
inject more ADVATE than recommended, tell your doctor as soon as possible.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you forget
to use ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not inject a double dose to make up for a forgotten dose. Proceed
with the next injection as scheduled and continue as advised by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you stop
using ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not stop
using ADVATE without consulting your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4. Possible side
effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all
medicines, </span><span lang=EN-GB>this medicine </span><span lang=EN-GB>can cause
side effects, although not everybody gets them.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If <b>severe, sudden allergic reactions</b> (anaphylactic) occur,
the injection <b>must be stopped immediately</b>. You must <b>contact your
doctor immediately</b> if you have any of the following early symptoms of
allergic reactions:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, hives, wheals, generalised itching,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of lips and tongue,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty in breathing, wheezing, tightness in
the chest,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>general feeling of being unwell,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness and loss of consciousness.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Severe symptoms, including difficulty in breathing and (nearly)
fainting, require prompt emergency treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For children not previously treated with Factor VIII medicines,
inhibitor antibodies (see section 2) may form very commonly (more than 1 in 10
people); however patients who have received previous treatment with Factor VIII
(more than 150 days of treatment) the risk is uncommon (less than 1 in 100
people). If this happens your or your childs medicines may stop working properly
and you or your child may experience persistent bleeding. If this happens, you
should contact your doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> (may affect
more than 1 in 10 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Factor VIII inhibitors</span><span lang=EN-GB> (for children not
previously treated with Factor VIII medicines). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> (may affect up to 1
in 10 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>headache and fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> (may affect up to 1
in 100 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Factor VIII inhibitors</span><span lang=EN-GB> (for patients who
have received previous treatment with Factor VIII (more than 150 days of treatment)),
dizziness, flu, fainting, abnormal heartbeat, red itchy bumps on the skin,
chest discomfort, injection site bruise, injection site reaction, itching,
increased sweating, unusual taste in the mouth, hot flushes, migraines, memory
impairment, chills, diarrhoea, nausea, vomiting, shortness of breath, sore
throat, infection of the lymphatic vessels, whitening of skin, eye
inflammation, rashes, excessive sweating, foot and leg swelling, reduced
percentage of red blood cells, increase in a type of white blood cells
(monocytes), and pain in the upper abdomen or lower chest.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Related to surgery</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>catheter&#8209;related infection, decreased red cell blood count, swelling
of limbs and joints, prolonged bleeding after drain removal, decreased Factor
VIII level and post&#8209;operative</span><span lang=EN-GB> bruise</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Related to central venous access devices (CVAD)</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>catheter&#8209;related infection, systemic infection and local blood
clot at the catheter site.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Side effects with unknown frequency</span></b><span lang=EN-GB>
(frequency cannot be estimated from the available data)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>potentially life&#8209;threatening
reactions (anaphylaxis) and other allergic reactions (hypersensitivity), general
disorders (tiredness, lack of energy).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Additional
side effects in children</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
side effects were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If </span><span lang=EN-GB>you get </span><span lang=EN-GB>any side
effects, talk to your doctor. </span><span lang=EN-GB>This includes any
possible</span><span lang=EN-GB> side effects not listed in this leaflet. </span><span
lang=EN-GB>You can also report side effects directly via the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>. </span><span lang=EN-GB>By reporting
side effects you can help provide more information on the safety of this
medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. How to store ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date, which is stated on
the label after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in a refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>During the shelf life the powder vial may be kept at room
temperature (up to&nbsp;25&nbsp;C) for a single period not exceeding&nbsp;6&nbsp;months.
</span><span lang=EN-GB>In this case, this medicine expires at the end of this
6&nbsp;month period or the expiration date printed on the product vial, whichever
is earlier. </span><span lang=EN-GB>Please record the end of the 6&nbsp;months
storage at room temperature on the product carton. The product may not be
returned to refrigerated storage after storage at room temperature.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep the vial in the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This product is for single use only. Discard any unused solution
appropriately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Use the product immediately once the powder is completely dissolved.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not refrigerate the solution after preparation.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via waste water or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.</span></b><b><span
lang=EN-GB> Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What ADVATE
contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is octocog alfa (human coagulation
Factor VIII produced by recombinant DNA technology). Each powder vial contains
nominally 250, 500, 1000, 1500, 2000, or 3000&nbsp;IU octocog alfa.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are mannitol, sodium chloride,
histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80, and
glutathione (reduced).</span></p>

<p class=MsoNormal style='line-height:normal'><a name="OLE_LINK4"><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></a></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Solvent vial:</span></i><span lang=EN-GB>&nbsp;5&nbsp;ml sterilised
water for injections</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What ADVATE looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is a
white to off&#8209;white friable powder. After reconstitution, the solution is
clear, colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Each pack also contains a device for reconstitution
(BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tel: </span><span lang=EL>+800 66838470</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>e-mail: medinfoEMEA@shire.com</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>Baxalta Belgium
Manufacturing SA</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Boulevard Ren Branquart&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>B&#8209;7860&nbsp;Lessines</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Belgium</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: <a href="http://www.ema.europa.eu/"><span style='color:windowtext;
text-decoration:none'>http://www.ema.europa.eu/</span></a></span></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Instructions for preparation and administration</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Aseptic technique is required during preparation of the solution and
administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Use only the sterilised water for injections and the reconstitution
device for preparation of the solution that are provided with each package of
ADVATE. ADVATE must not be mixed with other medicinal products or solvents.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly recommended
that every time ADVATE is administered, the name and batch number of the
product are recorded.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Instructions for reconstitution</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use after the expiry date stated on the
labels and carton.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration
as indicated by the symbol: <img border=0 width=29 height=28
src="Advate-h-520-e_files/image027.jpg">.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the solution after
preparation.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1. If the product is
still stored in a refrigerator, take both the ADVATE powder and solvent vials
from the refrigerator and let them reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Remove caps from powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Cleanse stoppers with alcohol swabs. Place
the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5.<b> </b>Open the package of BAXJECT&nbsp;II
device by peeling away the paper lid without touching the inside (Fig. a). Do
not remove the device from the package. Do not use if the BAXJECT II device,
its sterile barrier system or its packaging is damaged or shows any sign of
deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>6. Turn the package over
and insert the clear plastic spike through the solvent stopper. Grip the
package at its edge and pull the package off BAXJECT&nbsp;II (Fig. b). Do not
remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>7. For reconstitution
only the sterilised water for injections and the reconstitution device provided
in the pack should be used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on
top of the device. Insert the white plastic spike through the ADVATE powder stopper.
The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter. The
product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After
reconstitution the solution should be clear, colourless and free from foreign
particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a    Fig.
b   Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image028.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Instructions for injection</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For administration the use of a luer&#8209;lock syringe is required.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><u><span
lang=EN-GB>Important note</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not try to administer the injection unless
you have received special training from your doctor or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inspect the prepared solution for particulate
matter and discoloration prior to administration (the solution should be clear,
colourless and free from foreign particles).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt;line-height:
normal'><span lang=EN-GB>Do not use ADVATE if the solution is not fully clear
or not completely dissolved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II. <b>Do
not draw air into the syringe</b>. Connect the syringe to BAXJECT&nbsp;II (Fig.
d).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the reconstituted
solution has to be on top). Draw the reconstituted solution into the syringe by
pulling the plunger back slowly (Fig. e).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Attach a butterfly needle to the syringe and
inject the reconstituted solution into a vein. The solution should be administered
slowly, at a rate as determined by the patients comfort level, not to exceed&nbsp;10&nbsp;ml
per minute. (See Section&nbsp;4&nbsp;Possible side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>5. Discard any unused solution
appropriately.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=a><span lang=EN-GB>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Fig. d  Fig.
e</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB><img border=0 width=415 height=181
src="Advate-h-520-e_files/image029.jpg"></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following information is intended for healthcare professionals only:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>On demand
treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of the
following haemorrhagic events, the factor VIII activity should not fall below
the given plasma activity level (in % of normal or IU/dl) in the corresponding
period. The following table can be used to guide dosing in bleeding episodes and
surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The dose and frequency of administration should be adapted to the
clinical response in the individual case. Under certain circumstances (e.g.
presence of a low&#8209;titre inhibitor), doses larger than those calculated
using the formula may be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="34%" valign=top style='width:34.02%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
   haemorrhage/type of surgical procedure</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.34%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor VIII
   level required (% or IU/dl)</span></b></p>
   </td>
   <td width="40%" valign=top style='width:40.64%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency&nbsp;of&nbsp;doses&nbsp;(hours)/duration&nbsp;<br>
   of&nbsp;therapy&nbsp;(days)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="34%" valign=top style='width:34.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life&#8209;threatening
  haemorrhages.</span></p>
  </td>
  <td width="25%" valign=top style='width:25.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more
  until pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours
  for patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="34%" valign=top style='width:34.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText style='page-break-after:avoid'><span lang=EN-GB>Including
  tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>(pre&#8209; and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Every&nbsp;24&nbsp;hours (12&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6), at least&nbsp;1&nbsp;day, until healing is
  achieved.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Repeat injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) until adequate wound healing, then
  continue therapy for at least another&nbsp;7&nbsp;days to maintain a factor
  VIII activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>Package leaflet: Information for
the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU powder and solvent
for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU powder and
solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU powder and
solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU powder and
solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>ADVATE&nbsp;2000&nbsp;IU powder and
solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>ADVATE&nbsp;3000&nbsp;IU powder and
solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>octocog alfa (recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of this
leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor.
This includes any possible side effects not listed in this leaflet. See section
4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What is in this
leaflet</span></b><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. What ADVATE is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. What you need to know before you use ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. How to use ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. How to store ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. W</span></b><b><span
lang=EN-GB>hat ADVATE is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE contains the active substance octocog alfa, human coagulation
factor VIII produced by recombinant DNA technology. Factor VIII is necessary
for the blood to form clots and stop bleedings. In patients with haemophilia A
(inborn lack of factor VIII), it is missing or not working properly.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is used </span><span lang=EN-GB>for the treatment and
prevention of bleeding in patients of all age groups with haemophilia A (an
inherited bleeding disorder caused by lack of factor VIII).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is prepared without the addition of any human&#8209; or animal&#8209;derived
protein in the entire manufacturing process.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2. What you need to know before you use ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use
ADVATE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to octocog alfa or any of the
other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to mouse or hamster proteins</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are unsure
about this, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor before using ADVATE. </span><span lang=EN-GB>You should tell your doctor
if you have been previously treated with Factor VIII products, especially if
you developed inhibitors, since there might be a higher risk that it happens
again. Inhibitors are blocking antibodies against factor VIII that reduce the
efficacy of ADVATE to prevent or control bleeding. Development of inhibitors is
a known complication in the treatment of haemophilia A</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'>.</span></span><span
lang=EN-GB> If your bleeding is not controlled with ADVATE, tell your doctor
immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is a rare risk that you may experience an anaphylactic reaction
(a severe, sudden allergic reaction) to ADVATE. You should be aware of the early
signs of allergic reactions such as rash, hives, wheals, generalised itching,
swelling of lips and tongue, difficulty in breathing, wheezing, tightness in
the chest, general feeling of being unwell, and dizziness. These symptoms can constitute
an early symptom of an anaphylactic shock, manifestations of which may
additionally include extreme dizziness, loss of consciousness, and extreme
difficulty in breathing.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If any of these symptoms occur, stop the injection immediately and
contact your doctor. Severe symptoms, including difficulty in breathing and
(near) fainting, require prompt emergency treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Patients
developing Factor VIII inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
inhibitors (antibodies) is a known complication that can occur during treatment
with all Factor VIII medicines. These inhibitors, especially at high levels,
stop the treatment working properly and you or your child will be monitored
carefully for the development of these inhibitors. If you or your childs
bleeding is not being controlled with ADVATE, tell your doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Children and
adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed
warnings and precautions apply to both adults and children (from 0 to 18 years
of age).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other
medicines and ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tell your doctor if you are using, have recently used or might use any
other medicines.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pregnancy and
breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are pregnant
or breast-feeding, think you may be pregnant or are planning to have a baby, </span><span
lang=EN-GB>ask your doctor </span><span lang=EN-GB>for advice before using this
medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Driving and
using machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE has no
influence on your ability to drive or to use machines.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ADVATE
contains sodium</span></b></p>

<p class=MsoNormal style='line-height:normal'>This medicine contains 10 mg sodium
(main component of cooking salt) per vial. <span lang=EN-GB>This is equivalent
to 0.5 % of the recommended maximum daily dietary intake of sodium for an adult.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. How to use ADVATE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Treatment with ADVATE will be started by a doctor who is experienced
in the care of patients with haemophilia A.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will calculate your dose of ADVATE (in international
units or IU) depending on your condition and body weight, and on whether it is
used for prevention or treatment of bleeding. The frequency of administration
will depend on how well ADVATE is working for you. Usually, the replacement
therapy with ADVATE is a life&#8209;long treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always use </span><span lang=EN-GB>this medicine</span><span
lang=EN-GB> exactly as your doctor has told you. Check with your doctor if you are
not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Prevention of
bleeding</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The usual dose of octocog alfa is&nbsp;20&nbsp;to&nbsp;40&nbsp;IU
per kg body weight, administered every&nbsp;2&nbsp;to&nbsp;3&nbsp;days.
However, in some cases, especially in younger patients, more frequent
injections or higher doses may be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Treatment of bleeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The dose of octocog alfa is calculated depending on your body weight
and the factor VIII levels to be achieved. The target factor VIII levels will
depend on the severity and location of the bleeding.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose
(IU)&nbsp;=&nbsp;body weight (kg) x desired Factor VIII rise (% of normal)
x&nbsp;0.5</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have the impression that the effect of ADVATE is insufficient,
talk to your doctor.</span></p>

<p class=MsoBodyText3 align=left style='text-align:left;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-weight:normal;font-style:
normal'>Your doctor will perform appropriate laboratory tests to make sure that
you have adequate Factor VIII levels. This is particularly important if you are
having major surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Use in children
and adolescents</span></b><span lang=EN-GB> (from 0 to 18 years of age)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For the treatment of bleeding the dosing in children does not differ
from adult patients. For the prevention of bleeding in children under the age
of 6, doses of 20 to 50&nbsp;IU per kg body weight 3 to 4&nbsp;times weekly are
recommended. The administration of ADVATE in children (intravenously) does not
differ from the administration in adults. A central venous access device (CVAD)
may become necessary to allow frequent infusions of factor VIII products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>How ADVATE is
given</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is usually injected into a vein (intravenously) by your
doctor or nurse. You or someone else might also administer ADVATE as an
injection, but only after receiving adequate training. Detailed instructions
for self&#8209;administration are given at the end of this package leaflet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you use
more ADVATE than you should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take ADVATE exactly as your doctor has told you. You should
check with your doctor if you are not sure. </span><span lang=EN-GB>If you inject
more ADVATE than recommended, tell your doctor as soon as possible.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you forget
to use ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not inject a double dose to make up for a forgotten dose. Proceed
with the next injection as scheduled and continue as advised by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you stop
using ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not stop
using ADVATE without consulting your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all
medicines, </span><span lang=EN-GB>this medicine </span><span lang=EN-GB>can
cause side effects, although not everybody gets them.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If <b>severe, sudden allergic reactions</b> (anaphylactic) occur,
the injection <b>must be stopped immediately</b>. You must <b>contact your
doctor immediately</b> if you have any of the following early symptoms of
allergic reactions:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, hives, wheals, generalised itching,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of lips and tongue,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty in breathing, wheezing, tightness in the
chest,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>general feeling of being unwell,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness and loss of consciousness.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Severe symptoms, including difficulty in breathing and (nearly)
fainting, require prompt emergency treatment. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For children not previously treated with Factor VIII medicines, inhibitor
antibodies (see section 2) may form very commonly (more than 1 in 10 people); however
patients who have received previous treatment with Factor VIII (more than 150
days of treatment) the risk is uncommon (less than 1 in 100 people). If this
happens your or your childs medicines may stop working properly and you or your
child may experience persistent bleeding. If this happens, you should contact your
doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> (may affect
more than 1 in 10 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Factor VIII inhibitors</span><span lang=EN-GB> (for children not
previously treated with Factor VIII medicines). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> (may affect up to 1
in 10 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>headache and fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> (may affect up to
1 in 100 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Factor VIII inhibitors</span><span lang=EN-GB> (for patients who have
received previous treatment with Factor VIII (more than 150 days of treatment)),
dizziness, flu, fainting, abnormal heartbeat, red itchy bumps on the skin,
chest discomfort, injection site bruise, injection site reaction, itching,
increased sweating, unusual taste in the mouth, hot flushes, migraines, memory
impairment, chills, diarrhoea, nausea, vomiting, shortness of breath, sore throat,
infection of the lymphatic vessels, whitening of skin, eye inflammation, rashes,
excessive sweating, foot and leg swelling, reduced percentage of red blood
cells, increase in a type of white blood cells (monocytes), and pain in the
upper abdomen or lower chest.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Related to surgery</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>catheter&#8209;related infection, decreased red cell blood count,
swelling of limbs and joints, prolonged bleeding after drain removal, decreased
Factor VIII level and post&#8209;operative</span><span lang=EN-GB> bruise</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Related to central venous access devices (CVAD)</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>catheter&#8209;related infection, systemic infection and local blood
clot at the catheter site.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Side effects with unknown frequency</span></b><span lang=EN-GB>
(frequency cannot be estimated from the available data)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>potentially life&#8209;threatening
reactions (anaphylaxis) and other allergic reactions (hypersensitivity), general
disorders (tiredness, lack of energy).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Additional
side effects in children</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
side effects were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If </span><span lang=EN-GB>you get </span><span lang=EN-GB>any side effects,
talk to your doctor. </span><span lang=EN-GB>This includes any possible</span><span
lang=EN-GB> side effects not listed in this leaflet. </span><span lang=EN-GB>You
can also report side effects directly via the national reporting system listed
in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>. </span><span lang=EN-GB>By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. How to store ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date, which is stated on
the label after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in a refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>During the shelf life the blister with the product may be kept at
room temperature (up to&nbsp;25&nbsp;C) for a single period not
exceeding&nbsp;6&nbsp;months. </span><span lang=EN-GB>In this case, this medicine
expires at the end of this 6&nbsp;month period or the expiration date printed
on the </span><span lang=EN-GB>blister</span><span lang=EN-GB>, whichever is
earlier. </span><span lang=EN-GB>Please record the end of the 6&nbsp;months
storage at room temperature on the product carton. The product may not be
returned to refrigerated storage after storage at room temperature.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep the blister with the product in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This product is for single use only. Discard any unused solution
appropriately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Use the product immediately once the powder is completely dissolved.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not refrigerate the solution after preparation.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via waste water or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.</span></b><b><span
lang=EN-GB> Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What ADVATE
contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is octocog alfa (human coagulation
Factor VIII produced by recombinant DNA technology). Each powder vial contains
nominally 250, 500, 1000, 1500, 2000, or 3000&nbsp;IU octocog alfa.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are mannitol, sodium
chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
and glutathione (reduced).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Solvent vial:</span></i><span
lang=EN-GB>&nbsp;5&nbsp;ml sterilised water for injections</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What ADVATE
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE is a
white to off&#8209;white friable powder. After reconstitution, the solution is
clear, colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tel: </span><span lang=EL>+800 66838470</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>e-mail: medinfoEMEA@shire.com</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal'>Baxalta Belgium Manufacturing SA</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Boulevard Ren Branquart&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>B&#8209;7860&nbsp;Lessines</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Belgium</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: <a href="http://www.ema.europa.eu/"><span style='color:windowtext;
text-decoration:none'>http://www.ema.europa.eu/</span></a></span></p>

<div style='border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 1.0pt 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Instructions
for preparation and administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE must not be mixed with other medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered, the name and batch number
of the product are recorded.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Instructions
for reconstitution</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use after the expiry date stated on the
labels and carton.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the solution after
preparation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a
refrigerator, take <span style='color:black'>the</span> sealed blister
(contains powder and solvent vials preassembled with the system for reconstitution)
from the refrigerator and let it reach room temperature (between&nbsp;15&nbsp;C
and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the
BAXJECT&nbsp;III system, press down firmly on the solvent vial with the other
hand until the system is fully collapsed and the solvent flows down into the
ADVATE vial (Fig. 2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass through
the device filter. The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute).
After reconstitution the solution should be clear, colourless and free from
foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span class=a><b><span lang=PT style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span class=a><b><span lang=PT style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span class=a><b><span lang=PT style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image003.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image004.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Instructions for injection</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Aseptic technique is required during administration.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For administration the use of a luer&#8209;lock syringe is required.</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Important
note</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not try to administer the injection unless
you have received special training from your doctor or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inspect the prepared solution for particulate
matter and discoloration prior to administration (the solution should be clear,
colourless and free from foreign particles).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt;line-height:
normal'><span lang=EN-GB>Do not use ADVATE if the solution is not fully clear
or not completely dissolved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;III. <b>Do
not draw air into the syringe</b>. Connect the syringe to BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the reconstituted
solution has to be on top). Draw the reconstituted solution into the syringe by
pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Attach a butterfly needle to the syringe and
inject the reconstituted solution into a vein. The solution should be
administered slowly, at a rate as determined by the patients comfort level,
not to exceed&nbsp;10&nbsp;ml per minute. (See Section&nbsp;4&nbsp;Possible
side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>5. Discard any unused
solution appropriately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In case of the following haemorrhagic events, the factor VIII
activity should not fall below the given plasma activity level (in % of normal
or IU/dl) in the corresponding period. The following table can be used to guide
dosing in bleeding episodes and surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The dose and frequency of administration should be adapted to the
clinical response in the individual case. Under certain circumstances (e.g.
presence of a low&#8209;titre inhibitor), doses larger than those calculated using
the formula may be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="34%" valign=top style='width:34.02%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
   haemorrhage/type of surgical procedure</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.34%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor
   VIII level required (% or IU/dl)</span></b></p>
   </td>
   <td width="40%" valign=top style='width:40.64%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency&nbsp;of&nbsp;doses&nbsp;(hours)/duration&nbsp;<br>
   of&nbsp;therapy&nbsp;(days)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="34%" valign=top style='width:34.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life&#8209;threatening
  haemorrhages.</span></p>
  </td>
  <td width="25%" valign=top style='width:25.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="40%" valign=top style='width:40.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours
  (8&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6) for at
  least&nbsp;1&nbsp;day, until the bleeding episode, as indicated by pain, is
  resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more
  until pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;12&nbsp;hours for patients under the age of&nbsp;6) until
  threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="34%" valign=top style='width:34.02%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal;page-break-after:auto'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>Including tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal;page-break-after:auto'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal;page-break-after:auto'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(pre&#8209;
  and postoperative)</span></p>
  </td>
  <td width="40%" valign=top style='width:40.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Every&nbsp;24&nbsp;hours
  (12&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6), at least&nbsp;1&nbsp;day,
  until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6) until adequate wound healing, then continue
  therapy for at least another&nbsp;7&nbsp;days to maintain a factor VIII
  activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;250&nbsp;IU powder and solvent for solution for
injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;500&nbsp;IU powder and solvent for solution for
injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU powder and solvent for solution for
injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU powder and solvent for solution for
injection</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>octocog alfa (recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor.
This includes any possible side effects not listed in this leaflet. See section
4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What is in
this leaflet</span></b><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. What ADVATE is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. What you need to know before you use ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. How to use ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. How to store ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. W</span></b><b><span
lang=EN-GB>hat ADVATE is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE contains the active substance octocog alfa, human coagulation
factor VIII produced by recombinant DNA technology. Factor VIII is necessary for
the blood to form clots and stop bleedings. In patients with haemophilia A
(inborn lack of factor VIII), it is missing or not working properly.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is used </span><span lang=EN-GB>for the treatment and
prevention of bleeding in patients of all age groups with haemophilia A (an
inherited bleeding disorder caused by lack of factor VIII).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is prepared without the addition of any human&#8209; or
animal&#8209;derived protein in the entire manufacturing process.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2. What you need to know before you use ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use
ADVATE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to octocog alfa or any of the
other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to mouse or hamster proteins</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
unsure about this, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor before using ADVATE. </span><span lang=EN-GB>You should tell your doctor
if you have been previously treated with Factor VIII products, especially if you
developed inhibitors, since there might be a higher risk that it happens again.
Inhibitors are blocking antibodies against factor VIII that reduce the efficacy
of ADVATE to prevent or control bleeding. Development of inhibitors is a known
complication in the treatment of haemophilia A</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'>.</span></span><span
lang=EN-GB> If your bleeding is not controlled with ADVATE, tell your doctor
immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is a rare risk that you may experience an anaphylactic reaction
(a severe, sudden allergic reaction) to ADVATE. You should be aware of the early
signs of allergic reactions such as rash, hives, wheals, generalised itching,
swelling of lips and tongue, difficulty in breathing, wheezing, tightness in
the chest, general feeling of being unwell, and dizziness. These symptoms can
constitute an early symptom of an anaphylactic shock, manifestations of which
may additionally include extreme dizziness, loss of consciousness, and extreme
difficulty in breathing.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If any of these symptoms occur, stop the injection immediately and
contact your doctor. Severe symptoms, including difficulty in breathing and
(near) fainting, require prompt emergency treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Patients
developing Factor VIII inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
inhibitors (antibodies) is a known complication that can occur during treatment
with all Factor VIII medicines. These inhibitors, especially at high levels,
stop the treatment working properly and you or your child will be monitored
carefully for the development of these inhibitors. If you or your childs
bleeding is not being controlled with ADVATE, tell your doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Children and
adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed warnings
and precautions apply to both adults and children (from 0 to 18 years of age).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other
medicines and ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tell your doctor if you are using, have recently used or might use
any other medicines.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pregnancy and
breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant or breast-feeding, think you may be pregnant or are planning to have a
baby, </span><span lang=EN-GB>ask your doctor </span><span lang=EN-GB>for
advice before using this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Driving and
using machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE has no
influence on your ability to drive or to use machines.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ADVATE
contains sodium</span></b></p>

<p class=MsoNormal style='line-height:normal'>This medicine contains 10 mg sodium
(main component of cooking salt) per vial. <span lang=EN-GB>This is equivalent
to 0.5 % of the recommended maximum daily dietary intake of sodium for an adult.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Misapplication
of ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Misapplication (injection
into the artery or outside the vein) should be avoided as mild, short term
injection site reactions, such as bruising and redness, may occur.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. How to use ADVATE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Treatment with ADVATE will be started by a doctor who is experienced
in the care of patients with haemophilia A.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will calculate your dose of ADVATE (in international
units or IU) depending on your condition and body weight, and on whether it is used
for prevention or treatment of bleeding. The frequency of administration will
depend on how well ADVATE is working for you. Usually, the replacement therapy
with ADVATE is a life&#8209;long treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always use </span><span lang=EN-GB>this medicine</span><span
lang=EN-GB> exactly as your doctor has told you. Check with your doctor if you
are not sure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Prevention of bleeding</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The usual dose of octocog alfa
is&nbsp;20&nbsp;to&nbsp;40&nbsp;IU per kg body weight, administered
every&nbsp;2&nbsp;to&nbsp;3&nbsp;days. However, in some cases, especially in
younger patients, more frequent injections or higher doses may be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Treatment of
bleeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose of
octocog alfa is calculated depending on your body weight and the factor VIII
levels to be achieved. The target factor VIII levels will depend on the severity
and location of the bleeding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose
(IU)&nbsp;=&nbsp;body weight (kg) x desired Factor VIII rise (% of normal)
x&nbsp;0.5</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have the impression that the effect of ADVATE is
insufficient, talk to your doctor.</span></p>

<p class=MsoBodyText3 align=left style='text-align:left;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-weight:normal;font-style:
normal'>Your doctor will perform appropriate laboratory tests to make sure that
you have adequate Factor VIII levels. This is particularly important if you are
having major surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Use in
children and adolescents</span></b><span lang=EN-GB> (from 0 to 18 years of
age)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the
treatment of bleeding the dosing in children does not differ from adult patients.
For the prevention of bleeding in children under the age of 6, doses of 20 to
50&nbsp;IU per kg body weight 3 to 4&nbsp;times weekly are recommended. The
administration of ADVATE in children (intravenously) does not differ from the
administration in adults. A central venous access device (CVAD) may become
necessary to allow frequent infusions of factor VIII products. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
decrease in injection volume for ADVATE reconstituted in&nbsp;2&nbsp;ml, the
time to react to hypersensitivity reactions during an injection is further reduced.
Therefore, caution is advised during injection of ADVATE reconstituted in&nbsp;2&nbsp;ml,
especially in children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>How ADVATE is
given</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is usually injected into a vein (intravenously) by your
doctor or nurse. You or someone else might also administer ADVATE as an injection,
but only after receiving adequate training. Detailed instructions for self&#8209;administration
are given at the end of this package leaflet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you use
more ADVATE than you should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take ADVATE exactly as your doctor has told you. You should
check with your doctor if you are not sure. </span><span lang=EN-GB>If you inject
more ADVATE than recommended, tell your doctor as soon as possible.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you forget
to use ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not inject a double dose to make up for a forgotten dose. Proceed
with the next injection as scheduled and continue as advised by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you stop
using ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not stop
using ADVATE without consulting your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4. Possible side
effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all medicines,
</span><span lang=EN-GB>this medicine </span><span lang=EN-GB>can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If <b>severe, sudden allergic reactions</b> (anaphylactic) occur, the
injection <b>must be stopped immediately</b>. You must <b>contact your doctor
immediately</b> if you have any of the following early symptoms of allergic reactions:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, hives, wheals, generalised itching,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of lips and tongue,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty in breathing, wheezing, tightness in
the chest,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>general feeling of being unwell,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness and loss of consciousness.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Severe symptoms, including difficulty in breathing and (nearly)
fainting, require prompt emergency treatment. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For children not previously treated with Factor VIII medicines,
inhibitor antibodies (see section 2) may form very commonly (more than 1 in 10
people); however patients who have received previous treatment with Factor VIII
(more than 150 days of treatment) the risk is uncommon (less than 1 in 100 people).
If this happens your or your childs medicines may stop working properly and
you or your child may experience persistent bleeding. If this happens, you
should contact your doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> (may affect
more than 1 in 10 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Factor VIII inhibitors</span><span lang=EN-GB> (for children not
previously treated with Factor VIII medicines). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> (may affect up to 1
in 10 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>headache and fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> (may affect up to
1 in 100 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Factor VIII inhibitors</span><span lang=EN-GB> (for patients who
have received previous treatment with Factor VIII (more than 150 days of treatment)),
dizziness, flu, fainting, abnormal heartbeat, red itchy bumps on the skin, chest
discomfort, injection site bruise, injection site reaction, itching, increased
sweating, unusual taste in the mouth, hot flushes, migraines, memory
impairment, chills, diarrhoea, nausea, vomiting, shortness of breath, sore
throat, infection of the lymphatic vessels, whitening of skin, eye inflammation,
rashes, excessive sweating, foot and leg swelling, reduced percentage of red
blood cells, increase in a type of white blood cells (monocytes), and pain in
the upper abdomen or lower chest.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Related to surgery</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>catheter&#8209;related infection, decreased red cell blood count,
swelling of limbs and joints, prolonged bleeding after drain removal, decreased
Factor VIII level and post&#8209;operative</span><span lang=EN-GB> bruise</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Related to central venous access devices (CVAD)</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>catheter&#8209;related infection, systemic infection and local blood
clot at the catheter site.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Side effects with unknown frequency</span></b><span lang=EN-GB>
(frequency cannot be estimated from the available data)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>potentially life&#8209;threatening
reactions (anaphylaxis) and other allergic reactions (hypersensitivity), general
disorders (tiredness, lack of energy).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Additional side
effects in children</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in side
effects were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If </span><span lang=EN-GB>you get </span><span lang=EN-GB>any side
effects, talk to your doctor. </span><span lang=EN-GB>This includes any
possible</span><span lang=EN-GB> side effects not listed in this leaflet. Y</span><span
lang=EN-GB>ou can also report side effects directly via the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>. </span><span lang=EN-GB>By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. How to store ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date, which is stated on
the label after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in a refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>During the shelf life the powder vial may be kept at room temperature
(up to&nbsp;25&nbsp;C) for a single period not exceeding&nbsp;6&nbsp;months. </span><span
lang=EN-GB>In this case, this medicine expires at the end of this 6&nbsp;month
period or the expiration date printed on the product vial, whichever is earlier.
</span><span lang=EN-GB>Please record the end of the 6&nbsp;months storage at
room temperature on the product carton. The product may not be returned to
refrigerated storage after storage at room temperature.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep the vial in the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This product is for single use only. Discard any unused solution
appropriately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Use the product immediately once the powder is completely dissolved.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not refrigerate the solution after preparation.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via waste water or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.</span></b><b><span
lang=EN-GB> Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What ADVATE
contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is octocog alfa (human coagulation
Factor VIII produced by recombinant DNA technology). Each powder vial contains
nominally 250, 500, 1000, or 1500&nbsp;IU octocog alfa.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are mannitol, sodium
chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
and glutathione (reduced).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Solvent vial:</span></i><span
lang=EN-GB>&nbsp;2&nbsp;ml sterilised water for injections</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What ADVATE
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE is a white to off&#8209;white friable powder. After reconstitution,
the solution is clear, colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each pack also
contains a device for reconstitution (BAXJECT&nbsp;II).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tel: </span><span lang=EL>+800 66838470</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>e-mail: medinfoEMEA@shire.com</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal'>Baxalta Belgium Manufacturing SA</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Boulevard Ren Branquart&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>B&#8209;7860&nbsp;Lessines</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Belgium</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: <a href="http://www.ema.europa.eu/"><span
style='color:windowtext;text-decoration:none'>http://www.ema.europa.eu/</span></a></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Instructions for preparation and administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Aseptic technique is required during preparation of the solution and
administration.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Use only the sterilised water for injections and the reconstitution
device for preparation of the solution that are provided with each package of ADVATE.
ADVATE must not be mixed with other medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered, the name and batch number
of the product are recorded.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Instructions
for reconstitution</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use after the expiry date stated on the
labels and carton.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the BAXJECT II device, its sterile
barrier system or its packaging is damaged or shows any sign of deterioration
as indicated by the symbol: <img border=0 width=29 height=28
src="Advate-h-520-e_files/image027.jpg">.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the solution after preparation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1. If the product is
still stored in a refrigerator, take both the ADVATE powder and solvent vials
from the refrigerator and let them reach room temperature
(between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>2. Wash your hands
thoroughly </span><span lang=EN-GB>using soap and warm water</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>3. Remove caps from
powder and solvent vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>4.<b> </b>Cleanse
stoppers with alcohol swabs. Place the vials on a flat clean surface.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>5. Open the package of
BAXJECT&nbsp;II device by peeling away the paper lid without touching the
inside (Fig. a). Do not remove the device from the package. Do not use if the
BAXJECT II device, its sterile barrier system or its packaging is damaged or
shows any sign of deterioration.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>6. Turn the package over
and insert the clear plastic spike through the solvent stopper. Grip the
package at its edge and pull the package off BAXJECT&nbsp;II (Fig. b). Do not
remove the blue cap from the BAXJECT&nbsp;II device.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>7.<b> </b>For reconstitution
only the sterilised water for injections and the reconstitution device provided
in the pack should be used. With <span style='text-transform:uppercase'>Baxject&nbsp;II</span>
attached to the solvent vial, invert the system so that the solvent vial is on top
of the device. Insert the white plastic spike through the ADVATE powder stopper.
The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>8. Swirl gently until all
material is dissolved. Be sure that the ADVATE powder is completely dissolved,
otherwise not all reconstituted solution will pass through the device filter.
The product dissolves rapidly (usually in less than&nbsp;1&nbsp;minute). After reconstitution
the solution should be clear, colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Fig. a    Fig.
b     Fig. c</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB><img border=0 width=630
height=183 src="Advate-h-520-e_files/image028.jpg"></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Instructions for injection</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For administration the use of a luer&#8209;lock syringe is required.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Important
note</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not try to administer the injection unless
you have received special training from your doctor or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inspect the prepared solution for particulate matter
and discoloration prior to administration (the solution should be clear,
colourless and free from foreign particles).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt;line-height:
normal'><span lang=EN-GB>Do not use ADVATE if the solution is not fully clear
or not completely dissolved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. Remove the blue cap from BAXJECT&nbsp;II. <b>Do
not draw air into the syringe</b>. Connect the syringe to BAXJECT&nbsp;II (Fig.
d).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Invert the system (the vial with the
reconstituted solution has to be on top). Draw the reconstituted solution into
the syringe by pulling the plunger back slowly (Fig. e).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Attach a butterfly needle to the syringe and
inject the reconstituted solution into a vein. The solution should be administered
slowly, at a rate as determined by the patients comfort level, not to exceed&nbsp;10&nbsp;ml
per minute. (See Section&nbsp;4&nbsp;Possible side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>5. Discard any unused
solution appropriately.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=a><span lang=EN-GB>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><a
name="_Hlk22569223"><b><span lang=EN-GB>Fig. d  Fig.
e</span></b></a></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><a
name="_Hlk22565617"></a><a name="_Hlk22567777"><span lang=EN-GB><img border=0
width=415 height=181 src="Advate-h-520-e_files/image029.jpg"></span></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>On demand treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of the
following haemorrhagic events, the factor VIII activity should not fall below
the given plasma activity level (in % of normal or IU/dl) in the corresponding
period. The following table can be used to guide dosing in bleeding episodes
and surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose and
frequency of administration should be adapted to the clinical response in the individual
case. Under certain circumstances (e.g. presence of a low&#8209;titre inhibitor),
doses larger than those calculated using the formula may be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="32%" valign=top style='width:32.66%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Degree of haemorrhage/type of surgical procedure</span></b></p>
  </td>
  <td width="25%" valign=top style='width:25.04%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Factor VIII level required (% or IU/dl)</span></b></p>
  </td>
  <td width="42%" valign=top style='width:42.3%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Frequency of doses (hours)/duration of therapy (days)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.66%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText style='page-break-after:avoid'><span lang=EN-GB>Early
  haemarthrosis, muscle bleeding or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>More extensive haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Life&#8209;threatening haemorrhages.</span></p>
  </td>
  <td width="25%" valign=top style='width:25.04%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="42%" valign=top style='width:42.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Repeat injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours
  for patients under the age of&nbsp;6) for at least&nbsp;1&nbsp;day, until the
  bleeding episode, as indicated by pain, is resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Repeat injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours
  (8&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6)
  for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more until pain and acute disability are
  resolved.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Repeat injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;12&nbsp;hours for patients under the age of&nbsp;6) until
  threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.66%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText style='page-break-after:avoid'><span lang=EN-GB>Including
  tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.04%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>(pre&#8209; and postoperative)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Every&nbsp;24&nbsp;hours (12&nbsp;to&nbsp;24&nbsp;hours for
  patients under the age of&nbsp;6), at least&nbsp;1&nbsp;day, until healing is
  achieved.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Repeat injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6) until
  adequate wound healing, then continue therapy for at least
  another&nbsp;7&nbsp;days to maintain a factor VIII activity of&nbsp;30% to&nbsp;60%
  (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
text-indent:-28.35pt;line-height:normal'><b><span lang=EN-GB>Package leaflet:
Information for the user</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
text-indent:-28.35pt;line-height:normal'><b><span lang=EN-GB>ADVATE&nbsp;250&nbsp;IU
powder and solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
text-indent:-28.35pt;line-height:normal'><b><span lang=EN-GB>ADVATE&nbsp;500&nbsp;IU
powder and solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
text-indent:-28.35pt;line-height:normal'><b><span lang=EN-GB>ADVATE&nbsp;1000&nbsp;IU
powder and solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
text-indent:-28.35pt;line-height:normal'><b><span lang=EN-GB>ADVATE&nbsp;1500&nbsp;IU
powder and solvent for solution for injection</span></b></p>

<p class=MsoNormal align=center style='margin-left:28.35pt;text-align:center;
text-indent:-28.35pt;line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>octocog alfa (recombinant human coagulation factor VIII)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects talk to your doctor.
This includes any possible side effects not listed in this leaflet. See section
4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What is in
this leaflet</span></b><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. What ADVATE is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. What you need to know before you use ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. How to use ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. How to store ADVATE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1. W</span></b><b><span
lang=EN-GB>hat ADVATE is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE contains the active substance octocog alfa, human coagulation
factor VIII produced by recombinant DNA technology. Factor VIII is necessary
for the blood to form clots and stop bleedings. In patients with haemophilia A
(inborn lack of factor VIII), it is missing or not working properly.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is used </span><span lang=EN-GB>for the treatment and
prevention of bleeding in patients of all age groups with haemophilia A (an
inherited bleeding disorder caused by lack of factor VIII).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is prepared without the addition of any human&#8209; or
animal&#8209;derived protein in the entire manufacturing process.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2. What you need to know before you use ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use ADVATE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to octocog alfa or any of
the other ingredients of this medicine (listed in section 6)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to mouse or hamster proteins</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are unsure
about this, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor before using ADVATE. </span><span lang=EN-GB>You should tell your doctor
if you have been previously treated with Factor VIII products, especially if
you developed inhibitors, since there might be a higher risk that it happens
again. Inhibitors are blocking antibodies against factor VIII that reduce the
efficacy of ADVATE to prevent or control bleeding. Development of inhibitors is
a known complication in the treatment of haemophilia A</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'>.</span></span><span
lang=EN-GB> If your bleeding is not controlled with ADVATE, tell your doctor
immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is a rare risk that you may experience an anaphylactic
reaction (a severe, sudden allergic reaction) to ADVATE. You should be aware of
the early signs of allergic reactions such as rash, hives, wheals, generalised
itching, swelling of lips and tongue, difficulty in breathing, wheezing,
tightness in the chest, general feeling of being unwell, and dizziness. These
symptoms can constitute an early symptom of an anaphylactic shock,
manifestations of which may additionally include extreme dizziness, loss of consciousness,
and extreme difficulty in breathing.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If any of these symptoms occur, stop the injection immediately and
contact your doctor. Severe symptoms, including difficulty in breathing and
(near) fainting, require prompt emergency treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Patients developing
Factor VIII inhibitors</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The formation of
inhibitors (antibodies) is a known complication that can occur during treatment
with all Factor VIII medicines. These inhibitors, especially at high levels,
stop the treatment working properly and you or your child will be monitored
carefully for the development of these inhibitors. If you or your childs
bleeding is not being controlled with ADVATE, tell your doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Children and
adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The listed warnings
and precautions apply to both adults and children (from 0 to 18 years of age).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Other
medicines and ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tell your doctor if you are using, have recently used or might use any
other medicines.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pregnancy and
breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant or breast-feeding, think you may be pregnant or are planning to have a
baby, </span><span lang=EN-GB>ask your doctor </span><span lang=EN-GB>for
advice before using this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Driving and
using machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ADVATE has no
influence on your ability to drive or to use machines.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ADVATE
contains sodium</span></b></p>

<p class=MsoNormal style='line-height:normal'>This medicine contains 10 mg
sodium (main component of cooking salt) per vial. <span lang=EN-GB>This is
equivalent to 0.5 % of the recommended maximum daily dietary intake of sodium
for an adult.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Misapplication
of ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Misapplication
(injection into the artery or outside the vein) should be avoided as mild,
short term injection site reactions, such as bruising and redness, may occur.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3. How to use ADVATE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Treatment with ADVATE will be started by a doctor who is experienced
in the care of patients with haemophilia A.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your doctor will calculate your dose of ADVATE (in international units
or IU) depending on your condition and body weight, and on whether it is used
for prevention or treatment of bleeding. The frequency of administration will
depend on how well ADVATE is working for you. Usually, the replacement therapy
with ADVATE is a life&#8209;long treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always use </span><span lang=EN-GB>this medicine</span><span
lang=EN-GB> exactly as your doctor has told you. Check with your doctor if you
are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Prevention of bleeding</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The usual dose of octocog alfa is&nbsp;20&nbsp;to&nbsp;40&nbsp;IU
per kg body weight, administered every&nbsp;2&nbsp;to&nbsp;3&nbsp;days. However,
in some cases, especially in younger patients, more frequent injections or
higher doses may be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Treatment of
bleeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose of
octocog alfa is calculated depending on your body weight and the factor VIII
levels to be achieved. The target factor VIII levels will depend on the severity
and location of the bleeding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dose
(IU)&nbsp;=&nbsp;body weight (kg) x desired Factor VIII rise (% of normal)
x&nbsp;0.5</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have the impression that the effect of ADVATE is
insufficient, talk to your doctor.</span></p>

<p class=MsoBodyText3 align=left style='text-align:left;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-weight:normal;font-style:
normal'>Your doctor will perform appropriate laboratory tests to make sure that
you have adequate Factor VIII levels. This is particularly important if you are
having major surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Use in children
and adolescents</span></b><span lang=EN-GB> (from 0 to 18 years of age)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the
treatment of bleeding the dosing in children does not differ from adult patients.
For the prevention of bleeding in children under the age of 6, doses of 20 to
50&nbsp;IU per kg body weight 3 to 4&nbsp;times weekly are recommended. The
administration of ADVATE in children (intravenously) does not differ from the
administration in adults. A central venous access device (CVAD) may become
necessary to allow frequent infusions of factor VIII products. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the decrease
in injection volume for ADVATE reconstituted in&nbsp;2&nbsp;ml, the time to react
to hypersensitivity reactions during an injection is further reduced.
Therefore, caution is advised during injection of ADVATE reconstituted in&nbsp;2&nbsp;ml,
especially in children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>How ADVATE is
given</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>ADVATE is usually injected into a vein (intravenously) by your
doctor or nurse. You or someone else might also administer ADVATE as an
injection, but only after receiving adequate training. Detailed instructions
for self&#8209;administration are given at the end of this package leaflet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you use
more ADVATE than you should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take ADVATE exactly as your doctor has told you. You should
check with your doctor if you are not sure. </span><span lang=EN-GB>If you
inject more ADVATE than recommended, tell your doctor as soon as possible.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you forget
to use ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not inject a double dose to make up for a forgotten dose. Proceed
with the next injection as scheduled and continue as advised by your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you stop
using ADVATE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not stop
using ADVATE without consulting your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all
medicines, </span><span lang=EN-GB>this medicine </span><span lang=EN-GB>can
cause side effects, although not everybody gets them.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If <b>severe, sudden allergic reactions</b> (anaphylactic) occur,
the injection <b>must be stopped immediately</b>. You must <b>contact your
doctor immediately</b> if you have any of the following early symptoms of allergic
reactions:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, hives, wheals, generalised itching,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling of lips and tongue,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty in breathing, wheezing, tightness in
the chest,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>general feeling of being unwell,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness and loss of consciousness.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Severe symptoms, including difficulty in breathing and (nearly)
fainting, require prompt emergency treatment. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For children not previously treated with Factor VIII medicines, inhibitor
antibodies (see section 2) may form very commonly (more than 1 in 10 people);
however patients who have received previous treatment with Factor VIII (more
than 150 days of treatment) the risk is uncommon (less than 1 in 100 people).
If this happens your or your childs medicines may stop working properly and
you or your child may experience persistent bleeding. If this happens, you
should contact your doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> (may affect
more than 1 in 10 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Factor VIII inhibitors</span><span lang=EN-GB> (for children not previously
treated with Factor VIII medicines). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> (may affect up to 1
in 10 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>headache and fever.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB> (may affect up to
1 in 100 people)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Factor VIII inhibitors</span><span lang=EN-GB> (for patients who
have received previous treatment with Factor VIII (more than 150 days of treatment)),
dizziness, flu, fainting, abnormal heartbeat, red itchy bumps on the skin,
chest discomfort, injection site bruise, injection site reaction, itching,
increased sweating, unusual taste in the mouth, hot flushes, migraines, memory
impairment, chills, diarrhoea, nausea, vomiting, shortness of breath, sore
throat, infection of the lymphatic vessels, whitening of skin, eye inflammation,
rashes, excessive sweating, foot and leg swelling, reduced percentage of red blood
cells, increase in a type of white blood cells (monocytes), and pain in the
upper abdomen or lower chest.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Related to surgery</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>catheter&#8209;related infection, decreased red cell blood count,
swelling of limbs and joints, prolonged bleeding after drain removal, decreased
Factor VIII level and post&#8209;operative</span><span lang=EN-GB> bruise</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Related to central venous access devices (CVAD)</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>catheter&#8209;related infection, systemic infection and local blood
clot at the catheter site.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Side effects with unknown frequency</span></b><span lang=EN-GB>
(frequency cannot be estimated from the available data)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>potentially life&#8209;threatening
reactions (anaphylaxis) and other allergic reactions (hypersensitivity), general
disorders (tiredness, lack of energy).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Additional
side effects in children</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Other than the
development of inhibitors in previously untreated paediatric patients (PUPs),
and catheter&#8209;related complications, no age&#8209;specific differences in
side effects were noted in the clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If </span><span lang=EN-GB>you get </span><span lang=EN-GB>any side
effects, talk to your doctor. </span><span lang=EN-GB>This includes any
possible</span><span lang=EN-GB> side effects not listed in this leaflet. Y</span><span
lang=EN-GB>ou can also report side effects directly via the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext'>Appendix V</span></a>. </span><span lang=EN-GB>By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5. How to store ADVATE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date, which is stated on
the label after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in a refrigerator (2&nbsp;C &nbsp;8&nbsp;C).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>During the shelf life the blister with the product may be kept at
room temperature (up to&nbsp;25&nbsp;C) for a single period not
exceeding&nbsp;6&nbsp;months. </span><span lang=EN-GB>In this case, this
medicine expires at the end of this 6&nbsp;month period or the expiration date
printed on the </span><span lang=EN-GB>blister</span><span lang=EN-GB>,
whichever is earlier. </span><span lang=EN-GB>Please record the end of the
6&nbsp;months storage at room temperature on the product carton. The product
may not be returned to refrigerated storage after storage at room temperature.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep the blister with the product in the outer carton in order to
protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This product is for single use only. Discard any unused solution appropriately.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Use the product immediately once the powder is completely dissolved.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not refrigerate the solution after preparation.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via waste water or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.</span></b><b><span
lang=EN-GB> Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What ADVATE
contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is octocog alfa (human coagulation
Factor VIII produced by recombinant DNA technology). Each powder vial contains
nominally 250, 500, 1000, or 1500&nbsp;IU octocog alfa.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are mannitol, sodium
chloride, histidine, trehalose, calcium chloride, trometamol, polysorbate&nbsp;80,
and glutathione (reduced).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Solvent vial:</span></i><span
lang=EN-GB>&nbsp;2&nbsp;ml sterilised water for injections</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>What ADVATE
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE is a white to off&#8209;white friable powder. After
reconstitution, the solution is clear, colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Takeda Manufacturing Austria AG</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Industriestrasse&nbsp;67</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A&#8209;1221&nbsp;Vienna</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Tel: </span><span lang=EL>+800 66838470</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>e-mail: medinfoEMEA@shire.com</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal'>Baxalta Belgium Manufacturing SA</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Boulevard Ren Branquart&nbsp;80</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>B&#8209;7860&nbsp;Lessines</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>Belgium</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>This leaflet
was last revised in </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: <a href="http://www.ema.europa.eu/"><span
style='color:windowtext;text-decoration:none'>http://www.ema.europa.eu/</span></a></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Instructions for preparation and administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ADVATE must not be mixed with other medicinal products or solvents.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is strongly
recommended that every time ADVATE is administered, the name and batch number
of the product are recorded.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Instructions
for reconstitution</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use after the expiry date stated on the
labels and carton.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use if the lid is not completely sealed
on the blister</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not refrigerate the solution after preparation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1. If the product is still stored in a refrigerator,
take <span style='color:black'>the</span> sealed blister (contains powder and
solvent vials preassembled with the system for reconstitution) from the refrigerator
and let it reach room temperature (between&nbsp;15&nbsp;C and&nbsp;25&nbsp;C).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2. Wash your hands thoroughly </span><span
lang=EN-GB>using soap and warm water.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Open the ADVATE package by peeling away the
lid. <span style='color:black'>Remove </span>the BAXJECT&nbsp;III system <span
style='color:black'>from the blister</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Place the ADVATE on a flat surface with the solvent
vial on top (Fig. 1). The solvent vial has a blue stripe. Do not remove the
blue cap until instructed in a later step.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5. With one hand holding the ADVATE in the BAXJECT&nbsp;III
system, press down firmly on the solvent vial with the other hand until the
system is fully collapsed and the solvent flows down into the ADVATE vial (Fig.
2). Do not tilt the system until the transfer is complete.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6. Verify that the solvent transfer is complete.
Swirl gently until all material is dissolved. Be sure that the ADVATE powder is
completely dissolved, otherwise not all reconstituted solution will pass
through the device filter. The product dissolves rapidly (usually in less
than&nbsp;1&nbsp;minute). After reconstitution the solution should be clear,
colourless and free from foreign particles.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span class=a><b><span lang=PT style='font-size:11.0pt'>Fig.&nbsp;1</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span class=a><b><span lang=PT style='font-size:11.0pt'>Fig.&nbsp;2</span></b></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText align=center style='margin-bottom:0in;text-align:center;
  line-height:normal'><span class=a><b><span lang=PT style='font-size:11.0pt'>Fig.&nbsp;3</span></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=167 height=167
  src="Advate-h-520-e_files/image002.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=172 height=172
  src="Advate-h-520-e_files/image003.gif"></span></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=DocText style='margin-bottom:0in;line-height:normal'><span
  lang=X-NONE><img border=0 width=176 height=176
  src="Advate-h-520-e_files/image004.gif"></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Instructions for injection</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Aseptic technique is required during administration.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For administration the use of a luer&#8209;lock syringe is required.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Important
note</span></u><span lang=EN-GB>:</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not try to administer the injection unless
you have received special training from your doctor or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inspect the prepared solution for particulate
matter and discoloration prior to administration (the solution should be clear,
colourless and free from foreign particles).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-indent:28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>Do not use ADVATE if the
solution is not fully clear or not completely dissolved.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1. Remove the blue cap
from BAXJECT&nbsp;III. <b>Do not draw air into the syringe</b>. Connect the
syringe to BAXJECT&nbsp;III.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>2. Invert the system (the
vial with the reconstituted solution has to be on top). Draw the reconstituted
solution into the syringe by pulling the plunger back slowly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3. Disconnect the syringe.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4. Attach a butterfly needle to the syringe and
inject the reconstituted solution into a vein. The solution should be
administered slowly, at a rate as determined by the patients comfort level, not
to exceed&nbsp;10&nbsp;ml per minute. (See Section&nbsp;4&nbsp;Possible side
effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>5. Discard any unused
solution appropriately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>On demand
treatment</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In case of the
following haemorrhagic events, the factor VIII activity should not fall below
the given plasma activity level (in % of normal or IU/dl) in the corresponding
period. The following table can be used to guide dosing in bleeding episodes
and surgery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The dose and frequency of administration should be adapted to the
clinical response in the individual case. Under certain circumstances (e.g.
presence of a low&#8209;titre inhibitor), doses larger than those calculated
using the formula may be necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="32%" valign=top style='width:32.66%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Degree of
   haemorrhage/type of surgical procedure</span></b></p>
   </td>
   <td width="25%" valign=top style='width:25.04%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Factor
   VIII level required (% or IU/dl)</span></b></p>
   </td>
   <td width="42%" valign=top style='width:42.3%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency
   of doses (hours)/duration of therapy (days)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="32%" valign=top style='width:32.66%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Haemorrhage</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoEndnoteText><span lang=EN-GB>Early haemarthrosis, muscle bleeding
  or oral bleeding.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>More extensive
  haemarthrosis, muscle bleeding or haematoma.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Life&#8209;threatening
  haemorrhages.</span></p>
  </td>
  <td width="25%" valign=top style='width:25.04%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>20&nbsp;&nbsp;40</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60&nbsp;&nbsp;100</span></p>
  </td>
  <td width="42%" valign=top style='width:42.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat
  injections every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours
  (8&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6) for at
  least&nbsp;1&nbsp;day, until the bleeding episode, as indicated by pain, is
  resolved or healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;12&nbsp;to&nbsp;24&nbsp;hours (8&nbsp;to&nbsp;24&nbsp;hours for patients
  under the age of&nbsp;6) for&nbsp;3&nbsp;&nbsp;4&nbsp;days or more until
  pain and acute disability are resolved.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Repeat injections
  every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours (6&nbsp;to&nbsp;12&nbsp;hours for
  patients under the age of&nbsp;6) until threat is resolved.</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" valign=top style='width:32.66%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Surgery</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>Minor</span></h6>
  <p class=MsoEndnoteText style='page-break-after:avoid'><span lang=EN-GB>Including
  tooth extraction.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <h6 style='line-height:normal'><span lang=EN-GB>&nbsp;</span></h6>
  <h6 style='line-height:normal'><span lang=EN-GB>Major</span></h6>
  <p class=MsoEndnoteText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="25%" valign=top style='width:25.04%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>30&nbsp;&nbsp;60</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>80&nbsp;&nbsp;100</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>(pre&#8209; and postoperative)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.3%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Every&nbsp;24&nbsp;hours (12&nbsp;to&nbsp;24&nbsp;hours for patients
  under the age of&nbsp;6), at least&nbsp;1&nbsp;day, until healing is achieved.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Repeat injections every&nbsp;8&nbsp;to&nbsp;24&nbsp;hours
  (6&nbsp;to&nbsp;24&nbsp;hours for patients under the age of&nbsp;6) until adequate
  wound healing, then continue therapy for at least another&nbsp;7&nbsp;days to
  maintain a factor VIII activity of&nbsp;30% to&nbsp;60% (IU/dl).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
